

JO17 Rec'd PCT/PTO 27 JUN 2001

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				56001 (46342)	
				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <b>09/869540</b> )	
INTERNATIONAL APPLICATION NO. <b>PCT/JP99/07337</b>		INTERNATIONAL FILING DATE <b>27 DECEMBER 99</b>		PRIORITY DATE CLAIMED <b>28 DECEMBER 98</b>	
TITLE OF INVENTION <b>SCREENING METHOD</b>					
APPLICANT(S) FOR DO/EO/US <b>Masaaki MORI, Yukio SHIMOMURA, Shiro TAKEKAWA, Tsukasa SUGO, Yoshihiro ISHIBASHI, Chieko KITADA, Nobuhiro SUZUKI</b>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol> <p><b>Items 13 to 20 below concern document(s) or information included:</b></p> <ol style="list-style-type: none"> <li>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>19. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail</li> <li>23. <input checked="" type="checkbox"/> Other items or information:</li> </ol> <p><b>Form PCT/RO/101, Drawings FIG. 1-10 (10 pp), Form PCT/IPEA/416, PCT/IB/338, PCT/RO/105 (JP), PCT/IB/301 (US), PCT/IB/304, PCT/IPEA/408, PCT/IB/308, PCT/ISA/220</b></p>					

3718 Rec'd PCT/PTO 27 JUN 2001

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <b>09/1869540</b>	INTERNATIONAL APPLICATION NO. <b>PCT/JP99/07337</b>	ATTORNEY'S DOCKET NUMBER <b>56001 (46342)</b>
---	--	--


24. The following fees are submitted:				<b>CALCULATIONS PTO USE ONLY</b>	
<b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5)) :</b>					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1000.00</b>					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b>					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$710.00</b>					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690.00</b>					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$860.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<b>\$0.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	12 - 20 =	0	x \$18.00	<b>\$0.00</b>	
Independent claims	8 - 3 =	5	x \$80.00	<b>\$400.00</b>	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,260.00</b>	
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				<b>\$0.00</b>	
<b>SUBTOTAL =</b>				<b>\$1,260.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,260.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input checked="" type="checkbox"/>	<b>\$40.00</b>
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,300.00</b>	
				<b>Amount to be refunded</b>	<b>\$</b>
				<b>charged</b>	<b>\$</b>

- a. ☒ A check in the amount of **\$1,300.00** to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **04-1105**. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David G. Conlin, Esq. (Reg. No. 27,026)  
 John B. Alexander, Ph. D. (Reg. No. P-48,399)  
 Dike Bronstein Roberts & Cushman  
 Intellectual Property Practice Group  
 EDWARDS & ANGELL LLP  
 P. O. Box 9169  
 Boston, MA 02209  
 Telephone: (617) 439-4444


  
 \_\_\_\_\_  
 SIGNATURE  
**John B. Alexander**  
 \_\_\_\_\_  
 NAME  
**P-48,399**  
 \_\_\_\_\_  
 REGISTRATION NUMBER  
**June 27, 2001**  
 \_\_\_\_\_  
 DATE

# TRANSMITTAL LETTER TO THE UNITED STATES RECEIVING OFFICE

06-28-01

331869540

Date	6/27/2001
International Application No	PCT/JP99/07337
Attorney Docket No.	56001 (46342)



Certification under 37 CFR 1.10 (if applicable)

EL 730724302 US
Express Mail mailing number

JC17 Rec'd PCT/PTO 27 JUN 2001

JUNE 27, 2001
Date of Deposit

I hereby certify that the application/correspondence attached hereto is being deposited with the United States Postal Service Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of person mailing correspondence

Norah C. Sullivan
Typed or printed name of person mailing correspondence

## II. ☒ New International Application

TITLE	SCREENING METHOD
-------	------------------

Earliest priority date (Day/Month/Year)
28 DECEMBER, 1998

**SCREENING DISCLOSURE INFORMATION:** In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (Note: check as many boxes as apply):

- A. ☒ The invention disclosed was **not** made in the United States.
- B. ☒ There is no prior U.S. application relating to this invention.
- C. ☐ The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (NOTE: priority to these applications may or may not be claimed on form PCT/RO/101 (Request) and this listing does not constitute a claim for priority).

application no.		filed on	
application no.		filed on	

- D. ☐ The present international application ☐ is identical ☐ contains less subject matter than that found in the prior U.S. application(s) identified in paragraph C.
- E. ☐ The present international application ☐ contains additional subject matter not found in the prior U.S. application(s) identified in paragraph C. above. The additional subject matter is found on pages  and ☐ DOES NOT ALTER ☐ MIGHT BE CONSIDERED TO ALTER the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 U.S.C. 181 and 37 CFR 5.1. See 37 CFR 5.15

## III. ☐ A Response to an Invitation from the RO/US. The following document(s) is (are) enclosed:

- A. ☐ A Request for An Extension of Time to File a Response
- B. ☐ A Power of Attorney (General or Regular)
- C. ☐ Replacement pages:

pages		of the request (PCT/RO/101)	pages		of the figures
pages		of the description	pages		of the abstract
pages		of the claims			

- D. ☐ Submission of Priority Documents

Priority document		Priority document	
-------------------	--	-------------------	--

- E. ☒ Fees as specified on attached Fee Calculation sheet form PCT/RO/101 annex

## IV. ☐ A Request for Rectification under PCT 91 ☐ A Petition ☒ A Sequence Listing Diskette

## V. ☐ Other (please specify):

The person signing this form is the:

<input type="checkbox"/> Applicant
<input checked="" type="checkbox"/> Attorney/Agent (Reg. No.) P-48,399
<input type="checkbox"/> Common Representative

JOHN B. ALEXANDER, Ph. D.

Typed name of signer

Signature

10/PR15

09/869540

JC18 Rec'd PCT/PTO 2 7 JUN 2001

1

## SPECIFICATION

### SCREENING METHOD

#### 5 FIELD OF THE INVENTION

The present invention relates to a method for screening an antiobestic agent, an appetite modulator or the like, characterized by using SLC-1 (FEBS Letters 398 (1996) 253-258, etc.), which is an orphan receptor protein, or its salt and  
10 MCH (melanin concentrating hormone (Endocrinology, vol. 125, 1660-1665 (1989), etc.) or its derivative, or a salt thereof.

#### BACKGROUND ART

Human SLC-1 found in human genome (FEBS Letters 398  
15 (1996) 253-258) and rat SLC-1 found from a rat brain cDNA library (Biochimica et Biophysica Acta, 1401 (1998) 216-220) are collectively referred to as a G protein-coupled receptor or seven transmembrane receptor. They are one of many G protein-coupled receptor proteins called orphan receptors,  
20 because their ligands are unknown.

For determining ligands of these orphan G protein-coupled receptor proteins, there was no other general means but only to predict the ligands from similarity in the primary structures of these G protein-coupled receptor  
25 proteins. However, many orphan G protein-coupled receptor proteins are poor in homology to known receptors. Actually, it was difficult to predict the ligands only from the similarity in their primary structures, except that they are receptor subtypes of known ligands. On the other hand,  
30 since many orphan G protein-coupled receptor proteins were found by gene analysis, it is predicted that there will be still many other unknown ligands corresponding to those proteins. To date, however, only few ligands were identified for these organ G protein-coupled receptors. With respect  
35 to SLC-1, it has not been reported, either, if its ligand exists.



To survey ligands to the SLC-1 orphan receptor protein and establish a method for screening a compound, etc. characterized by using SLC-1 and its ligands have thus been the problems to be solved.

5

#### DISCLOSURE OF THE INVENTION

Using cells expressing SLC-1 encoding cDNA by a suitable means, the present inventors have succeeded in screening a polypeptide recognized by the receptor protein as a ligand, by assaying a specific cell stimulating (signal transduction) activity, etc. as an index and have found that the polypeptide is MCH (melanin concentrating hormone).

Furthermore, the present inventors have found that a compound capable of altering the binding property between the activator MCH or its salt and the SLC-1 or its salt described above can be screened.

The present inventors have also found that the amino acid sequence of human SLC-1 of the present invention is a novel sequence different from the amino acid sequence previously reported (FEBS Letters, 398 (1996) 253-258, WO 96/18651).

That is, the present invention provides the following features.

(1) A method for screening a compound or its salt that alters the binding property between a melanin concentrating hormone (MCH) or its salt and SLC-1 or its salt, which comprises use of the MCH or its derivative, or a salt thereof and SLC-1 or its salt.

(2) A kit for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, comprising the MCH or its derivative, or a salt thereof and SLC-1 or its salt.

(3) A compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, which is obtainable by using the screening method according to

(1) or the screening kit according to (2).

(4) A pharmaceutical composition comprising the compound or its salt according to (3).

(5) A compound or its salt according to (4), which is  
5 an antiobestic agent.

(6) A protein containing the amino acid sequence represented by SEQ ID NO:11, or a salt thereof.

(7) A DNA comprising a DNA containing a base sequence encoding the protein according to (6).


10 (8) A screening method according to (1) or a screening kit according to (2), wherein the MCH is a peptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:2.

(9) A screening method according to (1) or a screening  
15 kit according to (2), wherein the derivative is a peptide containing a partial sequence of the 5th to the 19th from the N terminus of the amino acid sequence represented by SEQ ID NO:2.

(10) A screening method according to (1) or a screening  
20 kit according to (2), wherein the derivative is MCH derivatized with a Bolton-Hunter reagent or a peptide derivatized with a Bolton-Hunter reagent and containing a partial sequence of the 5th to the 19th from the N terminus of the amino acid sequence represented by SEQ ID NO:2.

25 (11) MCH derivatized with a Bolton-Hunter reagent, or a peptide derivatized with a Bolton-Hunter reagent and containing a partial sequence of the 5th to the 19th from the N terminus of the amino acid sequence represented by SEQ ID NO:2 or its salt.

30 (12) A compound represented by formula:



or its salt.

Specifically, the SLC-1 used in the present invention includes the publicly known SLC-1 described above or its salt, as well as the following compounds.

(13) An SLC-1 containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:5 or SEQ ID NO:11, or its salt.

(14) An SLC-1 or its salt according to (13), which is a protein containing the amino acid sequence shown by SEQ ID NO:5 or SEQ ID NO:11, of which 1 to 30, preferably 1 to 10, amino acids are deleted, the amino acid sequence shown by SEQ ID NO:5 or SEQ ID NO:11, to (or in) which 1 to 30, preferably 1 to 10, amino acids are added (or inserted); or the amino acid sequence shown by SEQ ID NO:5 or SEQ ID NO:11, in which 1 to 30, preferably 1 to 10, amino acids are substituted with other amino acids.

Specifically, the MCH in the present invention includes the publicly known MCH described above or its salt, as well as the following compounds.

(15) An MCH containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:2, or its derivative, or a salt thereof.

(16) An MCH or its derivative, or a salt thereof according to (15), wherein the protein is a peptide containing the amino acid sequence shown by SEQ ID NO: 2, of which 1 to 10, preferably 1 to 5, amino acids are deleted, the amino acid sequence shown by SEQ ID NO: 2, to (or in) which 1 to 10, preferably 1 to 5, amino acids are added (or inserted); or the amino acid sequence shown by SEQ ID NO: 2, in which 1 to 10, preferably 1 to 5, amino acids are substituted with other amino acids.

FIG. 1 shows results obtained by assaying a cAMP synthesis inhibitory activity specific to CHO/SLC-1 cells on the HPLC fractions prepared from rat brain.

FIG. 2 shows a behavior of the rat brain-derived HPLC fraction #34 in REFERENCE EXAMPLE 1 on the cAMP synthesis inhibitory activity when treated with pronase.

FIG. 3 shows results obtained by assaying the CHO/SLC-1 cell-specific cAMP synthesis inhibitory activity on a fraction purified through an ODS column (Develosil ODS-UG-3) in REFERENCE EXAMPLE 3.

FIG. 4 shows a comparison in an amount of gene expression by in situ hybridization in the rat SLC-1 gene expression CHO cell line.

FIG. 5 shows a cAMP synthesis inhibitory activity of MCH in various concentrations on CHO/SLC-1 cells.

FIG. 6 shows an arachidonic acid metabolite release activity of MCH in various concentrations on CHO/SLC-1 cells.

FIG. 7 shows results obtained by assaying an agonist activity of MCH, MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19), using GTP $\gamma$ S-binding assay.

FIG. 8 shows results obtained by assaying an agonist activity of MCH, MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) derivatized with a non-isotope Bolton-Hunter reagent, using GTP $\gamma$ S-binding assay.

FIG. 9 shows specific binding of [ $^{125}$ I]-labeled MCH(4-19) prepared using a Bolton-Hunter reagent to a cell membrane fraction prepared from human SLC-1-expression CHO cells.

FIG. 10 shows a binding inhibition activity of MCH against [ $^{125}$ I]-labeled MCH(4-19) prepared using a Bolton-Hunter reagent.

#### BEST MODE OF EMBODIMENT OF THE INVENTION

In the present specification, the term "substantially the same" is used to mean that the activities of polypeptides,

etc., e.g., the binding property between a ligand (MCH) and a receptor (SLC-1), physical activities, etc. are substantially the same.

Methods of manufacturing the SLC-1 or its salts (hereinafter sometimes collectively referred to as SLC-1) and the MCH or its derivatives or salts thereof (hereinafter sometimes collectively referred to as MCH), which are employed in the present invention, are described below in further detail.

The SLC-1 and MCH employed in the present invention may be any polypeptide derived from any tissues (e.g., pituitary, pancreas, brain, kidney, liver, genital gland, thyroid gland, gall bladder, spinal cord, adrenal, skin, muscle, lung, digestive tract, blood vessel, heart, etc.) or cells, etc., of human, other warm-blooded animals (e.g., guinea pig, rat, mouse, swine, sheep, bovine, monkey, etc.) and fish, etc., in which SLC-1 may be any polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:5 or SEQ ID NO:11 and MCH may be any polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:2. Examples of the SLC-1 of the present invention include, in addition to the polypeptide or the like containing the amino acid sequence shown by SEQ ID NO:5 or SEQ ID NO:11, a polypeptide or the like which has an activity substantially equivalent to the polypeptide containing the amino acid sequence shown by SEQ ID NO:5 or SEQ ID NO:11. Examples of the substantially equivalent activity include a ligand binding activity, a signal transduction activity, and the like. The term substantially equivalent means that the nature of the ligand binding activity, etc. is equivalent. Therefore, differences in degree such as a level of the ligand binding activity and quantitative factors such as a molecular weight of the polypeptide may be present and allowable. Examples

of the MCH of the present invention include, in addition to the polypeptide containing the amino acid sequence shown by SEQ ID NO:2, a polypeptide which has an activity substantially equivalent to the polypeptide containing the amino acid sequence shown by SEQ ID NO:2. Examples of the  
5 substantially equivalent activity include a receptor binding activity, and the like. The term substantially equivalent is used to mean that the nature of the receptor binding activity, etc. is equivalent. Therefore,  
10 differences in degree such as a level of the receptor binding activity and quantitative factors such as a molecular weight of the polypeptide may be present and allowable.

In the present specification, the SLC-1 and MCH are represented in accordance with the conventional way of  
15 describing peptides, that is, the N-terminus (amino terminus) at the left hand and the C-terminus (carboxyl terminus) at the right hand. For example, in a polypeptides containing the amino acid sequence shown by SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:11, the C-terminus is usually in  
20 the form of a carboxyl group (-COOH) or a carboxylate (-COO<sup>-</sup>) but may also be in the form of an amide (-CONH<sub>2</sub>) or an ester (-COOR). Examples of the ester group shown by R include a C<sub>1-6</sub> alkyl group such as methyl, ethyl, n-propyl, isopropyl, n-butyl, etc.; a C<sub>3-8</sub> cycloalkyl group such as cyclopentyl,  
25 cyclohexyl, etc.; a C<sub>6-12</sub> aryl group such as phenyl,  $\alpha$ -naphthyl, etc.; a phenyl-C<sub>1-2</sub> alkyl group, e.g., benzyl, phenethyl, benzhydryl, etc.; a C<sub>7-14</sub> aralkyl such as an  $\alpha$ -naphthyl-C<sub>1-2</sub> alkyl group, e.g.,  $\alpha$ -naphthylmethyl, etc.; and the like. In addition, pivaloyloxymethyl or the like which is widely  
30 used as an ester for oral administration may be used as well.

The SLC-1 and MCH of the present invention may be used in the form of salts with physiologically acceptable bases (e.g., alkali metals) or acids (e.g., inorganic acids or organic acids), preferably in the form of physiologically  
35 acceptable acid addition salts. Examples of such salts are

salts with inorganic acids (e.g., hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid), salts with organic acids (e.g., acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid) and the like.

The SLC-1 and MCH used in the present invention may be manufactured by modified methods of publicly known methods (e.g., those described in FEBS Letters, 398 (1996) 253-258, WO 96/18651), that is, methods used to purify polypeptides from tissues or cells of human or other warm-blooded animal. Alternatively, the SLC-1 and MCH may also be manufactured by modifications of the methods for synthesis of proteins (peptides), which will be described hereinafter.

Furthermore, the SLC-1 and MCH may be manufactured by culturing a transformant containing a DNA encoding the protein (peptide), which will also be later described.

Where the SLC-1 and MCH are manufactured from the tissues or cells of human, other warm-blooded animal, fish, etc., the tissues or cells of human, other warm-blooded animal or fish, etc. are homogenized. The homogenate is then extracted with an acid, an organic solvent or the like. The extract is purified and separated by means of salting-out, dialysis, gel filtration, or a combination of chromatography techniques such as reverse phase chromatography, ion exchange chromatography, affinity chromatography, etc.

As described above, the SLC-1 and MCH used in the present invention can be manufactured by publicly known methods for synthesis of proteins (peptides) or by cleaving proteins (peptides) containing the SLC-1 and/or MCH with an appropriate peptidase. For synthesis of proteins (peptides), for example, either solid phase synthesis or liquid phase synthesis may be used. That is, a partial peptide or amino acids capable of constructing the SLC-1 and/or MCH are condensed with the remaining part. When the product contains

protecting groups, the desired protein (peptide) can be obtained by removing the protecting groups. The publicly known methods for condensation and those for removal of protecting groups include the methods described in 1) - 5) below.

- 1) M. Bodanszky & M.A. Ondetti: Peptide Synthesis, Interscience Publishers, New York (1966)
- 2) Schroeder & Luebke: The Peptide, Academic Press, New York (1965)
- 3) Nobuo Izumiya, et al.: *Peptide Gosei-no-Kiso to Jikken* (Basics and experiments of peptide synthesis), published by Maruzen Co. (1975)
- 4) Haruaki Yajima & Shunpei Sakakibara: *Seikagaku Jikken Koza* (Biochemical Experiment) 1, *Tanpakushitsu no Kagaku* (Chemistry of Proteins) IV, 205 (1977)
- 5) Haruaki Yajima ed.: *Zoku Iyakuhin no Kaihatsu* (A sequel to Development of Pharmaceuticals), Vol. 14, Peptide Synthesis, published by Hirokawa Shoten

20

After completion of the reaction, the protein (peptide) may be purified and isolated by a combination of conventional purification methods such as solvent extraction, distillation, column chromatography, liquid chromatography, recrystallization, etc. When the protein (peptide) obtained by the above methods is in a free form, the protein (peptide) can be converted into an appropriate salt by a publicly known method; when the protein (peptide) is obtained in a salt form, it can be converted into a free form by a publicly known method.

30

To synthesize the amides of SLC-1 and MCH, commercially available resins that are suitably used for amide formation may be used. Examples of such resins include chloromethyl resin, hydroxymethyl resin, benzhydrylamine resin, aminomethyl resin, 4-benzyloxybenzyl alcohol resin,

35



4-methylbenzhydrylamine resin, PAM resin,  
4-hydroxymethylmethylphenyl acetamidomethyl resin,  
polyacrylamide resin,  
4-(2',4'-dimethoxyphenyl-hydroxymethyl)phenoxy resin,  
5 4-(2',4'-dimethoxyphenyl-Fmoc-aminoethyl) phenoxy resin,  
etc. Using these resins, amino acids in which  $\alpha$ -amino groups  
and functional groups on the side chains are appropriately  
protected are condensed on the resin, in accordance with  
the order of the sequence of the objective peptide, by various  
10 condensation methods publicly known in the art. At the end  
of the reaction, the protein (peptide) is excised from the  
resin and at the same time, the various protecting groups  
are removed. Then, an intramolecular disulfide bond-forming  
reaction is carried out, if necessary, in a highly diluted  
15 solution to obtain the objective protein (peptide).

For condensation of the protected amino acids described  
above, a variety of activating reagents that can be used  
for proteins (peptides) synthesis may be used. In particular,  
carbodiimides are preferably employed. Examples of such  
20 carbodiimides include DCC, N,N'-diisopropylcarbodiimide,  
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, etc. For  
activation by these reagents, the protected amino acids in  
combination with a racemization inhibitor (e.g., HOBt, HOObt,  
etc.) are added directly to the resin, or the protected amino  
25 acids are previously activated into the corresponding  
symmetric acid anhydrides, HOBt esters or HOObt esters,  
followed by adding the thus activated protected amino acids  
to the resin. Solvents suitably used to activate the  
protected amino acids or condense with the resin may be  
30 appropriately selected from solvents that are known to be  
usable for condensation reactions of proteins (peptides).  
Examples of such solvents are acid amides such as  
N,N-dimethylformamide, N,N-dimethylacetamide,  
N-methylpyrrolidone, etc.; halogenated hydrocarbons such  
35 as methylene chloride, chloroform, etc.; alcohols such as

20        Examples of the protecting groups used to protect the  
starting amino groups include Z, Boc, t-pentyloxycarbonyl,  
isobornyloxycarbonyl, 4-methoxybenzyloxycarbonyl, Cl-Z,  
Br-Z, adamantyloxycarbonyl, trifluoroacetyl, phthaloyl,  
formyl, 2-nitrophenylsulphenyl, diphenylphosphinothioyl,  
25        Fmoc, etc. Examples of the protecting group R for a carboxyl  
group include, in addition to those examples for the C<sub>1-6</sub>  
alkyl group, the C<sub>3-8</sub> cycloalkyl group and the C<sub>7-14</sub> aralkyl  
group described hereinabove, 2-adamantyl, 4-nitrobenzyl,  
4-methoxybenzyl, 4-chlorobenzyl, phenacyl and  
30        benzyloxycarbonylhydrazide, t-butoxycarbonylhydrazide,  
tritylhydrazide, and the like.

The hydroxyl group of serine and threonine can be protected through, for example, esterification or etherification. Examples of groups appropriately used for the esterification include a lower alkanoyl group such as

acetyl, etc., an aroyl group such as benzoyl group, and a group derived from carbon such as benzyloxycarbonyl group and ethoxycarbonyl group. Examples of groups appropriately used for the etherification include benzyl group,  
5 tetrahydropyranyl group, t-butyl group, etc.

Examples of groups for protecting the phenolic hydroxyl group of tyrosine include Bzl, Cl<sub>2</sub>-Bzl, 2-nitrobenzyl, Br-Z, t-butyl, etc.

Examples of groups used to protect the imidazole moiety  
10 of histidine include Tos,  
4-methoxy-2,3,6-trimethylbenzenesulfonyl, DNP,  
benzyloxymethyl, Bum, Boc, Trt, Fmoc, etc.

Examples of the activated carboxyl groups in the starting materials include the corresponding acid  
15 anhydrides, azides, activated esters [esters with alcohols (e.g., pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, HONB, N-hydroxysuccimide, N-hydroxyphthalimide, HOBt)]. As the activated amino groups in the starting material, the  
20 corresponding phosphoric amides are employed.

To eliminate (split off) the protecting groups, there are used catalytic hydrogenation in a hydrogen gas flow in the presence of a catalyst such as Pd-black or Pd-carbon; a treatment with an acid, for example, anhydrous hydrogen  
25 fluoride, methanesulfonic acid, trifluoromethanesulfonic acid, trifluoroacetic acid, a mixture thereof, etc.; a treatment with a base, for example, diisopropylethylamine, triethylamine, piperidine, piperazine, etc.; reduction with sodium in liquid ammonia; and the like. Elimination  
30 of the protecting groups by the acid treatment described above is carried out generally at a temperature of approximately -20°C to 40°C. In the acid treatment, addition of a cation scavenger such as anisole, phenol, thioanisole, m-cresol, p-cresol, dimethyl sulfide, 1,4-butanedithiol,  
35 1,2-ethanedithiol or the like is effective. Also,

2,4-dinitrophenyl group used for protecting the imidazole protecting group of histidine is removed by a treatment with thiophenol. Formyl group used for protecting the indole protecting group of tryptophan is eliminated by the aforesaid  
5 acid treatment in the presence of 1,2-ethanedithiol or 1,4-butanedithiol, as well as by a treatment with an alkali such as a dilute sodium hydroxide solution, dilute ammonia, etc.

Publicly known groups and means can be appropriately  
10 selected for protection of a functional group which should not participate in the reaction of the starting material and its protecting group as well as removal of the protecting group, activation of a functional group which participates in the reaction, and the like.

15 In another method for obtaining the amides of SLC-1 and MCH, the  $\alpha$ -carboxyl group of the carboxyl terminal amino acid is first amidated; the peptide chain is then extended toward the amino group side to have a desired chain length. Then, only the protecting group of the N-terminal  $\alpha$ -amino  
20 group of the resultant peptide is removed to obtain a protein. Likewise, another peptide (or amino acid) is manufactured by removing only the protecting group of the C-terminal carboxyl group. The two peptides are condensed with each other in a solvent mixture as described above. The details  
25 of the condensation reaction are the same as described above. After the protected peptide obtained by the condensation is purified, all the protecting groups are removed by the methods described above to give the desired crude protein (peptide). After purifying the crude protein (peptide) by  
30 various known means for purification, the main fraction is lyophilized to give the amide of the desired protein (peptide).

To prepare the esters of SLC-1 and MCH, the  $\alpha$ -carboxyl group of the carboxy terminal amino acid is condensed with  
35 a desired alcohol to prepare the amino acid ester, which

is then treated in a manner similar to the preparation of the amides of protein(peptide) to give the esters of the desired protein(peptide).

The MCH derivative used in the present invention may be any peptide of ① a partial peptide of MCH, ② a peptide wherein the constituent amino acids of MCH are deleted, other amino acids are added to the constituent amino acids or the constituent amino acids are substituted with other amino acids, or ③ MCH, the partial peptide described in ① or the peptide described in ②, which is labeled, etc., so long as it is capable of binding to SLC-1.

Specific examples of the partial peptide of MCH include a peptide containing a partial sequence of the 5th to the 19th from the N terminus of the amino acid sequence represented by SEQ ID NO:2, or its amides or esters, or salts thereof. More specifically, the partial peptides are a peptide containing the amino acid sequence shown by SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23 or SEQ ID NO:24, or its amides or esters, or salts thereof.

When the screening later described is carried out using the SLC-1, a peptide particularly preferably containing the amino acid sequence shown by SEQ ID NO:21, its amides or esters, or salts thereof are preferably used.

Examples of the peptides wherein the constituent amino acids of MCH are deleted, other amino acids are added to the constituent amino acids or the constituent amino acids are replaced by other amino acids include those shown by SEQ ID NO:2, wherein at least 1 or 2 (preferably about 1 to about 10, more preferably, several (1 or 2)) amino acids are deleted; at least 1 or 2 (preferably about 1 to about 10, more preferably about 1 to about 5 and most preferably several (1 or 2)) amino acids are added to the amino acid sequence; or, at least 1 or 2 (preferably about 1 to about 10, more preferably about 1 to about 5 and most preferably several (1 or 2)) amino acids are replaced by other amino

acids; and the like.

Substantially the same substitution of an amino acid in the amino acid sequences can be selected from, e.g., other amino acids of the class to which the amino acid belongs.

5 Examples of non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, methionine and the like. Examples of polar (neutral) amino acids are glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, and  
10 the like. Examples of positively charged (basic) amino acids are arginine, lysine, histidine, and the like. Examples of negatively charged (acidic) amino acids include aspartic acid, glutamic acid, and the like.

However, the location at which other amino acids are  
15 deleted or substituted as described above is preferably at the position other than Cys in the constituent amino acids of MCH.

As the labeled forms of MCH, the peptide described in ① or the peptide described in ②, there are isotope-labeled  
20 forms, fluorescence-labeled forms (fluorescent labeling with, e.g., fluorescein), biotinylated forms, enzyme-labeled forms, etc., by publicly known methods.

Specifically, MCH labeled with [ $^3\text{H}$ ], [ $^{125}\text{I}$ ], [ $^{14}\text{C}$ ], [ $^{35}\text{S}$ ], etc. by publicly known methods can be utilized. In particular,  
25 labeled forms of MCH or its derivatives, which are prepared by a publicly known method using a Bolton-Hunter reagent, may be utilized as well.

Specific examples of the labeled form of the MCH or its derivatives include the following compounds:

30 (1)


[ $^{125}\text{I}$ ] - [N - (3 - (4 - Hydroxy - 3 - iodophenyl) propionyl) - Asp<sup>1</sup>] - MC  
H



[illegible]

5


[<sup>125</sup>I] - [N- (3- (4-Hydroxy-3-iodophenyl) propionyl) -Arg<sup>6</sup>] -MC  
H (6-19)



10

[<sup>125</sup>I] - [N - (3 - (4 - Hydroxy - 3 - iodophenyl) propionyl) - Cys<sup>7</sup>] - MC  
H(7-19)

15



Among them,

20 [125I] - [N - (3 - (4-hydroxy-3-iodophenyl)propionyl) - Met<sup>4</sup>] - MC  
H(4-19) is particularly preferably employed.

As the salts of MCH or its derivatives, examples are the same as those given for the salts of SLC-1 and MCH described above.

25           The DNA encoding the SLC-1 used in the present invention



may be any DNA so long as it contains a DNA containing a DNA having a base sequence encoding a protein containing the same or substantially the same amino acid sequence as represented by SEQ ID NO:5 or SEQ ID NO:11. The DNA encoding the MCH used in the present invention may be any DNA so long as it contains a DNA containing a DNA having a base sequence encoding a peptide containing the same or substantially the same amino acid sequence as represented by SEQ ID NO:2. Also, the DNA may be any one of genomic DNA, a genomic DNA library, cDNA derived from the cells or tissues described above, a cDNA library derived from the cells or tissues described above and synthetic DNA. The vector used for the library may be any of bacteriophage, plasmid, cosmid, phagemid, etc. In addition, the DNA can be directly amplified by reverse transcriptase polymerase chain reaction (hereinafter abbreviated as RT-PCR technology) using an RNA fraction prepared from the cells or tissues described above.

More specifically, there are employed (1) a DNA that is hybridizable under stringent conditions to the sequence possessed by a DNA containing a DNA having a base sequence encoding a protein or peptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:11, (2) a DNA that is not hybridizable due to degeneracy of genetic code to the sequence possessed by a DNA containing a DNA having a base sequence encoding a protein or peptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:11 and to the sequence defined in (1) above but encoding a protein or peptide having the same amino acid sequence, etc. The hybridization can be carried out by publicly known methods or by modified known methods. The stringent conditions described above are, for example, conditions of 42°C, 50% formamide, 4 x SSPE (1 x SSPE = 150 mM NaCl, 10 mM NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O, 1 mM EDTA, pH 7.4),

5 x Denhardt's solution and 0.1% SDS.

The DNA encoding the SLC-1 or MCH used in the present invention can also be manufactured by the following genetic engineering techniques.

5 As a means for cloning of the DNA that fully encodes the SLC-1 or MCH of the present invention, the objective DNA may be selected by either amplification of the DNA from the DNA library, etc. *supra* by publicly known PCR using a synthetic DNA primer containing a partial base sequence of  
10 the SLC-1 or MCH of the present invention or, hybridization of the DNA inserted into an appropriate vector, e.g., with a labeled DNA fragment having a part or entire region of the base sequence encoding SLC-1 or MCH, or a labeled synthetic DNA. The hybridization can be carried out, for  
15 example, according to the method described in Molecular Cloning (2nd ed.; J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). When a commercially available library is used, the hybridization may be performed in accordance with the protocol described in the attached instructions.

20 The cloned DNA encoding the SLC-1 or MCH used in the present invention can be used as it is, depending upon purpose or, if desired, after digestion with a restriction enzyme or after addition of a linker thereto. The DNA may contain ATG as a translation initiation codon at the 5' end thereof  
25 and TAA, TGA or TAG as a translation termination codon at the 3' end thereof. These translation initiation and termination codons may also be added to the DNA, using an appropriate synthetic DNA adapter.

The expression vector of the SLC-1 or MCH used in the  
30 present invention can be manufactured, for example, by (a) excising the objective DNA fragment from the DNA encoding the SLC-1 or MCH used in the present invention and then (b) ligating the DNA fragment with an appropriate expression vector downstream a promoter in the vector.

35 Examples of the vector include plasmids derived from

35 If necessary and desired, a signal sequence that matches

with a host is added to the N-terminal side of the polypeptide or its partial peptide. Examples of the signal sequence that can be utilized are pho A signal sequence, OmpA signal sequence, etc. when the host is bacteria of the genus  
5 *Escherichia*;  $\alpha$ -amylase signal sequence, subtilisin signal sequence, etc. when the host is bacteria of the genus *Bacillus*; mating factor  $\alpha$  (MF $\alpha$ ) signal sequence, invertase signal sequence, etc. when the host is yeast; and insulin  
10 molecule signal sequence,  $\alpha$ -interferon signal sequence, antibody respectively.

Using the vector containing the thus constructed DNA encoding the SLC-1 or MCH, transformants can be manufactured.

As the host, there may be employed, for example, bacteria  
15 belonging to the genus *Escherichia*, bacteria belonging to the genus *Bacillus*, yeast, insects or insect cells, animal cells, etc.

Specific examples of the bacteria belonging to the genus *Escherichia* include *Escherichia coli* K12 DH1 (Proc. Natl.  
20 Acad. Sci. U.S.A., 60, 160 (1968)), JM103 (Nucleic Acids Research, 9, 309 (1981)), JA221 (Journal of Molecular Biology, 120, 517 (1978)), HB101 (Journal of Molecular Biology, 41, 459 (1969)), C600 (Genetics, 39, 440 (1954)), etc.

Examples of the bacteria belonging to the genus *Bacillus*  
25 include *Bacillus subtilis* MI114 (Gene, 24, 255 (1983)), 207-21 (Journal of Biochemistry, 95, 87 (1984)), etc.

Examples of yeast include *Saccharomyces cerevisiae* AH22, AH22R, NA87-11A, DKD-5D, 20B-12, etc.

As the insect, for example, a larva of *Bombyx mori* can  
30 be used (Maeda et al., Nature, 315, 592 (1985)).

Examples of insect cells that are used include *Spodoptera frugiperda* cells (Sf cell), MG1 cells derived from mid-intestine of *Trichoplusia ni*, High Five<sup>TM</sup> cells derived from egg of *Trichoplusia ni*, cells derived from  
35 *Mamestra brassicae*, cells derived from *Estigmena acrea*, etc.

for AcNPV virus; and for BmNPV virus, *Bombyx mori* N cells (BmN cell), etc. Examples of the Sf cells which can be used are Sf9 cells (ATCC CRL1711), Sf21 cells [both cells are described in Vaughn, J. L. et al., *In vitro*, 13, 213-217 (1977)], etc.

Examples of animal cells include monkey COS-7 cells, Vero cells, Chinese hamster CHO cells, DHFR gene deficient Chinese hamster CHO cells (dhfr<sup>-</sup> CHO cells), mouse L cells, mouse 3T3 cells, mouse myeloma cells, human HEK293 cells, human FL cells, 293 cells, C127 cells, BALB3T3 cells, Sp-2/O cells, etc.

Bacteria belonging to the genus *Escherichia* can be transformed, for example, by the method described in *Proc. Natl. Acad. Sci. U.S.A.*, 69, 2110 (1972) or *Gene*, 17, 107 (1982), etc.

Bacteria belonging to the genus *Bacillus* can be transformed, for example, by the method described in *Molecular & General Genetics*, 168, 111 (1979), etc.

Yeast can be transformed, for example, by the method described in *Proc. Natl. Acad. Sci. U.S.A.*, 75, 1929 (1978).

Insect cells or insects can be transformed, for example, according to the method described in *Bio/Technology*, 6, 47-55 (1988), etc.

Animal cells can be transformed, for example, according to the method described in *Virology*, 52, 456 (1973).

Methods for introducing the expression vectors into the cells include, for example, the lipofection method [Felgner, P. L. et al., *Proceedings of the National Academy of Sciences of the United States of America*, 84, 7413 (1987)], the calcium phosphate method [Graham, F. L. and van der Eb, A. J., *Virology*, 52, 456-467 (1973)], the electroporation method [Nuemann, E. et al., *EMBO J.*, 1, 841-845 (1982)], etc.

As described above, transformants transformed with the expression vector containing a DNA encoding the SLC-1 or

MCH used in the present invention are obtained.

For stably expressing the SLC-1 or MCH used in the present invention with animal cells, there is applicable a method for selecting the cells by clone selection in which the expression vectors transfected to animal cells are  
5 incorporated into chromosomes. Specifically, the transformants are selected using as an index the selection marker described above. Further by repeating the clone selection on the animal cells thus obtained using the  
10 selection marker, the stable animal cell line capable of highly expressing the SLC-1 or MCH used in the present invention can be obtained. Furthermore, when the dhfr gene is used as the selection marker, cultivation can be performed by gradually increasing a level of MTX to select resistant  
15 cells so that the DNA encoding the SLC-1 or MCH used in the present invention can be amplified in the cells together with the dhfr gene to obtain the animal cell line of higher expression.

The transformant described above is cultivated under  
20 conditions in which the DNA encoding the SLC-1 or MCH used in the present invention can be expressed, to produce and accumulate the polypeptide of the present invention. Thus, the SLC-1 or MCH used in the present invention can be manufactured.

25 Where the host is a bacterium belonging to the genus Escherichia or the genus Bacillus, the transformant can be appropriately cultivated in a liquid medium which contains materials required for growth of the transformant, such as carbon sources, nitrogen sources, inorganic materials, etc.  
30 Examples of the carbon sources include glucose, dextrin, soluble starch, sucrose, etc. Examples of the nitrogen sources include inorganic or organic materials such as ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extract, soybean cake, potato extract, etc. Examples  
35 of the inorganics are calcium chloride, sodium

dihydrogenphosphate, magnesium chloride, etc. In addition, yeast, vitamins, growth promoting factors, etc. may also be added to the medium. Preferably, pH of the medium is adjusted to about 5 to about 8.

5 A preferred example of the medium for cultivation of the bacteria belonging to the genus *Escherichia* is M9 medium supplemented with glucose and a amino acid (Miller, Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York, 1972). If necessary and desired,  
10 a chemical such as 3 $\beta$ -indolylacrylic acid can be added to the medium thereby to activate the promoter efficiently.

Where the host is a bacterium belonging to the genus *Escherichia*, the transformant is usually cultivated at about 15 to about 43°C for about 3 hours to about 24 hours. If  
15 necessary and desired, the culture may be aerated or agitated.

Where the host is a bacterium belonging to the genus *Bacillus*, the transformant is cultivated generally at about 30°C to about 40°C for about 6 hours to about 24 hours. If  
20 necessary and desired, the culture can be aerated or agitated.

Examples of media for cultivating the transformant whose host is a yeast include Burkholder's minimal medium [Bostian, K. L. et al., Proc. Natl. Acad. Sci. U.S.A., 77, 4505 (1980)]  
25 or in SD medium containing 0.5% casamino acid [Bitter, G. A. et al., Proc. Natl. Acad. Sci. U.S.A., 81, 5330 (1984)]. Preferably, pH of the medium is adjusted to about 5 to about 8. In general, the transformant is cultivated at about 20°C to about 35°C for about 24 hours to about 72 hours. If necessary  
30 and desired, the culture can be aerated or agitated.

Examples of media for cultivating the transformant whose host is an insect cell include Grace's Insect Medium (Grace, T. C. C., Nature, 195, 788 (1962)) supplemented with 10% inactivated bovine serum, etc. as appropriate additives.  
35 Preferably, pH of the medium is adjusted to about 6.2 to

about 6.4. Normally, the transformant is cultivated at about 27°C for about 3 days to about 5 days and, if necessary and desired, the culture can be aerated or agitated.

Examples of media for cultivating the transformant whose host is an animal cell include MEM medium containing about 5% to about 20% fetal bovine serum [Science, 122, 501 (1952)], DMEM medium [Virology, 8, 396 (1959)], RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)], etc. Preferably, pH of the medium is adjusted to about 6 to about 8. The transformant is usually cultivated at about 30°C to about 40°C for about 15 hours to about 60 hours and, if necessary and desired, the culture can be aerated or agitated.

Especially when CHO(dhfr<sup>r</sup>) cells and the dhfr gene are employed as the selection markers, it is preferred to use substantially thymidine-free DMEM supplemented with dialyzed bovine fetal serum.

The SLC-1 or MCH used in the present invention can be separated and purified from the culture described above by the following procedures.

For extracting the SLC-1 or MCH used in the present invention from the cultured bacteria or cells, publicly known methods can be used suitably, including a method in which transformants or cells are collected after cultivation, then suspended in an appropriate buffer and disrupted using ultrasonication, a treatment with lysozyme and/or freeze-thaw cycling, followed by centrifugation, filtration, etc. Thus, the crude extract of the SLC-1 or MCH used in the present invention can be obtained. The buffer used for the procedures may contain a protein denaturant such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100 (trademark, hereinafter sometimes abbreviated as TM), etc.

When the SLC-1 or MCH used in the present invention



is secreted in the culture broth, after completion of the cultivation the supernatant can be separated from the transformant or cell to collect the supernatant by a publicly known method.

5       The SLC-1 or MCH used in the present invention, which is contained in the thus-obtained culture supernatant or the extract, can be purified by appropriately combining the publicly known methods for separation and purification. Such known methods for separation and purification include a  
10   method utilizing difference in solubility such as salting out, solvent precipitation, etc.; a method mainly utilizing difference in molecular weight such as dialysis, ultrafiltration, gel filtration, SDS-polyacrylamide gel electrophoresis, etc.; a method utilizing difference in  
15   electric charges such as ion exchange chromatography, etc.; a method utilizing specific affinity such as affinity chromatography, etc.; a method utilizing difference in hydrophobicity such as reverse phase high performance liquid chromatography, etc.; a method utilizing difference in  
20   isoelectric point such as isoelectric focusing, chromatofocusing, etc.; and the like.

      When the SLC-1 or MCH used in the present invention thus obtained is in a free form, it can be converted into the salt by publicly known methods or modifications thereof.  
25   On the other hand, when the SLC-1 or MCH is obtained in a salt form, it can be converted into the free form or a different salt form by publicly known methods or modifications thereof.

      The SLC-1 or MCH used in the present invention, which is produced by the recombinant, can be treated with an  
30   appropriate protein modifying enzyme prior to or after the purification to suitably modify the SLC-1 or MCH or partially delete a protein (peptide) therefrom. Examples of the protein modifying enzyme include trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase and the like.  
35   Also, for deletion of the N-terminal amino acid, the publicly

known Edman method using Edman reagent (phenyl isothiocyanate) can be used.

The existence of the thus formed SLC-1 or MCH used in the present invention can be assayed by enzyme immunoassay  
5 using a specific antibody, or the like.

(2) A method for screening a compound or its salt that alters the binding property between the MCH or its salt and the SLC-1 or its salt, characterized by using the MCH or its derivative or a salt thereof and the SLC-1 or its salt,  
10 or a kit for screening a compound or its salt that alters the binding property between the MCH or its salt and the SLC-1 or its salt, characterized by using the MCH or its labeled form a salt thereof and the SLC-1 or its salt (hereinafter merely referred to as the screening methods  
15 of the present invention and the screening kits of the present invention, respectively) are described below in detail.

By using SLC-1 or its salt, or by constructing a expression system of recombinant SLC-1 and using a binding assay system (ligand/receptor assay system) between the MCH  
20 or its derivative or a salt thereof using the expression system, a compound or its salt that alters the binding property between the MCH or its salt and the SLC-1 or its salt (e.g., a peptide, a protein, a non-peptide compound, a synthetic compound, a fermentation product, etc.) can be  
25 screened.

Examples of such compounds include compounds showing SLC-1-mediated cell-stimulating activities (e.g., the activities that accelerate or suppress release of arachidonic acid, release of acetylcholine, release of  
30 intracellular  $\text{Ca}^{2+}$ , intracellular cAMP production, intracellular cGMP production, inositol phosphate production, changes in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, pH reduction, etc.) (namely, SLC-1 agonists),  
35 compounds having no such cell-stimulating activities

(namely, SLC-1 antagonists) and the like. The term "alters the binding property between the MCH or its salt and the SLC-1 or its salt" includes both cases that the binding property between MCH or its salt and SLC-1 or its salt is inhibited and binding to the ligand is accelerated.

That is, the present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt described above, which comprises comparing (i) the case that the MCH or its derivative or a salt thereof is brought into contact with the SLC-1 or its salt, and (ii) the case that the MCH or its derivative or a salt thereof and a test compound are brought into contact with the SLC-1 or its salt.

In the screening method of the present invention, the comparison is made by measuring, e.g., the amount of the ligand bound to the SLC-1 or its salt, the cell-stimulating activities, etc., (i) when the MCH or its derivative or a salt thereof is brought into contact with the SLC-1 or its salt, and (ii) when the MCH or its derivative or a salt thereof and a test compound are brought into contact with the SLC-1 or its salt; and comparing (i) and (ii).

More specifically, the screening method of the present invention provides the following features.

(1) A method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, which comprises measuring and comparing the binding amounts of the labeled MCH or its derivative or a salt thereof bound to the aforesaid SLC-1 or its salt, when the labeled MCH or its derivative or a salt thereof (when using the aforesaid "labeled MCH, etc. or its salt" as the "MCH derivative or its salt", no further labeling is necessary; hereinafter the same) is brought in contact with the SLC-1 or its salt and when the labeled MCH or its derivative or a salt thereof and a test compound are brought in contact with the SLC-1 or its salt.

(4) A method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, which comprises measuring and comparing SLC-1-mediated cell stimulating activities (e.g., activities that accelerate or suppress release of arachidonic acid, release of acetylcholine, release of intracellular  $\text{Ca}^{2+}$ , intracellular cAMP production, intracellular cGMP production, inositol phosphate production, change in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, pH reduction, etc.), when a compound for activating SLC-1 (e.g., MCH or its derivative or a salt thereof) is

brought in contact with a SLC-1-containing cell and when a compound for activating SLC-1 and a test compound are brought in contact with the SLC-1-containing cell.

(5) A method for screening a compound or its salt that  
 5 alters the binding property between MCH or its salt and SLC-1 or its salt, which comprises measuring and comparing SLC-1-mediated cell stimulating activities (e.g., activities that accelerate or suppress release of arachidonic acid, release of acetylcholine, release of  
 10 intracellular  $Ca^{2+}$ , intracellular cAMP production, intracellular cGMP production, inositol phosphate production, change in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, pH reduction, etc.), when a compound for activating  
 15 SLC-1 (e.g., MCH or its derivative or a salt thereof) is brought in contact with the SLC-1 expressed on a cell membrane by culturing a transformant containing the DNA encoding the SLC-1 and when a compound for activating the SLC-1 and a test compound are brought in contact with the SLC-1 expressed  
 20 on a cell membrane by culturing a transformant containing a DNA encoding SLC-1; and the like.

The screening method of the present invention is specifically described below.

First, the SLC-1 used for the screening method of the  
 25 present invention may be any material so long as it contains the aforesaid SLC-1. Preferred SLC-1 includes membrane fractions from the organs of human, warm-blooded animals, fish, etc. Since it is very difficult to obtain human-derived organs, the SLC-1 expressed in large quantities by using  
 30 recombinants is suitable for use in the screening. Particularly in human SLC-1, use of the SLC-1 containing the amino acid sequence shown by SEQ ID NO:11 can provide screening with good sensitivity, as compared to the SLC-1 represented by the previously reported amino acid sequence  
 35 (FEBS Letters, 398 (1996) 253-258, etc.).

For manufacturing the SLC-1, the procedure described above may be used.

When the SLC-1-containing cells or cell membrane fractions, etc. are employed in the screening method of the present invention, the cells or cell membrane fractions may be prepared by the method which will be described hereinafter.

Where the SLC-1-containing cells are used, the cells may be fixed using glutaraldehyde, formalin, etc. The fixation can be made by publicly known methods.

The SLC-1-containing cells refer to host cells that have expressed SLC-1. Examples of host cells include *Escherichia coli*, *Bacillus subtilis*, yeast, insect cells, animal cells, etc., described above.

The membrane fraction refers to a fraction abundant in cell membrane obtained by publicly known methods after cell disruption. Useful cell disruption methods include cell squashing using a Potter-Elvehjem homogenizer, disruption using a Waring blender or a polytron (manufactured by Kinematica Inc.), disruption by ultrasonication, and disruption by spraying cells through thin nozzles under an increased pressure using a French press or the like. Cell membrane fractionation is effected mainly by fractionation using a centrifugal force, such as fractionation centrifugation, density gradient centrifugation, etc. For example, cell disruption fluid is centrifuged at a low speed (500 rpm to 3,000 rpm) for a short period of time (normally about 1 minute to about 10 minutes) and, the resulting supernatant is centrifuged at a higher speed (15,000 rpm to 30,000 rpm) normally for 30 minutes to 2 hours. The precipitate thus obtained is used as the membrane fraction. The membrane fraction is rich in the SLC-1 expressed and membrane components such as cell-derived phospholipids and membrane proteins.

The amount of SLC-1 in the SLC-1-containing cells or

in the membrane fractions is preferably  $10^3$  to  $10^8$  molecules per cell, more preferably  $10^5$  to  $10^7$  molecules per cell. As the amount of expression increases, the ligand binding activity per unit of membrane fraction (specific activity) increases so that not only the highly sensitive screening system can be constructed but also large quantities of sample fluids can be assayed with the same lot.

To perform the above (1) through (3) for screening the compound that alters the binding property between MCH or its salt and SLC-1, an appropriate SLC-1 fraction and a labeled ligand or a compound containing a ligand activity (MCH or its derivative) are employed. The SLC-1 fraction is preferably a naturally occurring SLC-1 fraction or a recombinant SLC-1 fraction having an activity equivalent to that of the natural SLC-1 fraction. Herein, the term "equivalent activity" is intended to mean a ligand binding activity or the like, equivalent to that of the natural SLC-1 fraction. As the labeled ligand or the compound having a ligand activity, there are used a labeled ligand and a compound having a ligand activity (MCH or its derivative), etc. For example, a ligand (MCH or its derivative) which is labeled with  $[^3\text{H}]$ ,  $[^{125}\text{I}]$ ,  $[^{14}\text{C}]$ ,  $[^{35}\text{S}]$ , etc. can be utilized. In particular, the labeled form of the MCH derivative prepared by a publicly known method using a Bolton-Hunter reagent may also be utilized.

Specific examples of the labeled form of the MCH derivatives are compounds given in (1) through (7) described above.

Specifically, the compound that alters the binding property between MCH or its salt and SLC-1 is screened by the following procedures. First, a standard receptor preparation is prepared by suspending SLC-1-containing cells or membrane fractions of such cells in a buffer appropriate for screening. Any buffer can be used so long as it does not interfere with ligand-receptor binding, such

buffers including a phosphate buffer, a Tris-HCl buffer,  
 etc. showing pH of 4 to 10 (desirably pH of 6 to 8). For  
 the purpose of reducing non-specific binding, a surfactant  
 such as CHAPS, Tween-80<sup>TM</sup> (Kao-Atlas Inc.), digitonin,  
 5 deoxycholate, etc. may optionally be added to the buffer.  
 Further for the purpose of suppressing the degradation of  
 SLC-1 and MCH or its derivative caused by a protease, a  
 protease inhibitor such as PMSF, leupeptin, E-64  
 (manufactured by Peptide Institute, Inc.), pepstatin, etc.  
 10 may also be added. A given amount (5,000 cpm to 500,000 cpm)  
 of the labeled MCH or its derivative is added to 0.01 ml  
 to 10 ml of the receptor solution and at the same time, a  
 test compound of  $10^{-4}$  to  $10^{-1}$   $\mu$ M is allowed to be co-present.  
 To determine the amount of non-specific binding (NSB), a  
 15 reaction tube added with unlabeled MCH or its derivative  
 in a large excess is also prepared. The reaction is carried  
 out at approximately 0°C to 50°C, preferably 4°C to 37°C for  
 20 minutes to 24 hours, preferably 30 minutes to 3 hours.  
 After completion of the reaction, the reaction mixture is  
 20 filtrated through a glass fiber filter paper, etc. and washed  
 with a suitable volume of the same buffer. The residual  
 radioactivity retained on the glass fiber filter paper is  
 then measured with a liquid scintillation counter or a  $\gamma$   
 -counter. When a count (B-NSB<sub>0</sub>) obtained by subtracting  
 25 non-specific binding (NSB) from a count (B<sub>0</sub>) in the absence  
 of an antagonistic substance is taken as 100%, the test  
 compound giving a non-specific binding (B-NSB) of, e.g.,  
 50% or less can be selected as a candidate substance having  
 a competitive inhibitory activity.

30 For assaying the binding between SLC-1 and MCH or its  
 derivative, BIAcore (manufactured by Amersham Pharmacia  
 Biotech Co.) may also be employed. In this technique, the  
 MCH or its derivative is immobilized onto a sensor chip by  
 the amino coupling method following the protocol attached  
 35 to the device. A buffer such as phosphate buffer, Tris buffer,



etc., which contains SLC-1 purified from the SLC-1-containing cells or a transformant containing a DNA encoding SLC-1, or a membrane fraction containing SLC-1 or, the purified SLC-1 or a membrane fraction containing SLC-1 and a test compound, is passed over the sensor chip at a flow rate of 2 to 20  $\mu$ l/min. By monitoring that the test compound co-present alters the change in surface plasmon resonance caused by binding of MCH or its derivative on the sensor chip to SLC-1, the compound that alters the binding between SLC-1 and MCH can be screened. According to this technique, the alteration can be likewise measured by the procedure which involves immobilizing SLC-1 onto a sensor chip and passing over the sensor chip a buffer solution such as phosphate buffer, Tris buffer, etc., which contains MCH or its derivative or MCH or its derivative and a test compound. Examples of the test compound are the same as those given above.

The procedure (4) or (5) described above for screening the compound that alters the binding property between MCH or its salt and SLC-1 or its salt can be performed as follows. The SLC-1-mediated cell-stimulating activities (e.g., the activities that promote or suppress release of arachidonic acid, release of acetylcholine, release of intracellular  $\text{Ca}^{2+}$ , intracellular cAMP production, intracellular cGMP production, inositol phosphate production, change in cell membrane potential, phosphorylation of intracellular proteins, activation of c-fos, pH reduction, etc.) may be assayed by a publicly known method, or using an assay kit commercially available. Specifically, the SLC-1-containing cells are first cultivated on a multiwell plate, etc. Prior to screening, the medium is replaced with a fresh medium or with an appropriate non-cytotoxic buffer, followed by incubation for a given period of time in the presence of a test compound, etc. Subsequently, the cells are extracted or the supernatant is recovered. The formed product is

quantified by the respective procedures. Where it is difficult to detect the production of the index substance (e.g., arachidonic acid) for the cell-stimulating activities due to degrading enzymes contained in the cells, an inhibitor against such a degradation enzyme may be added prior to the assay. For detecting activities such as the cAMP production inhibitory activity, the baseline production in the cells is increased by forskolin or the like. Then, the suppressing effect on the increased baseline production can be detected.

For screening by assaying the cell-stimulating activities, a suitable cell in which SLC-1 has been expressed is required. Such a cell that the SLC-1 of the present invention has been expressed is desirably the aforesaid recombinant SLC-1-expression cell line, and the like. The SLC-1-expression cell may be either a stably expressed strain or a transiently expressed strain. Also, kind of animal cells is the same as those given above.

Examples of the test compound include a peptide, a protein, a non-peptide compound, a synthetic compound, a fermentation product, a cell extract, a plant extract, an animal tissue extract and the like.

In more detail, the following assay system employed for the ligand-receptor assay system *supra* is described below.

(1) When a receptor expression cell is stimulated by a receptor agonist, G protein in the cell is activated and GTP is bound thereto. This phenomenon is observed also in a membrane fraction of the receptor expression cell. Usually, GTP is hydrolyzed into GDP. However, when GTP $\gamma$ S is previously added to the reaction solution, GTP $\gamma$ S is bound to G protein as in GTP but is not hydrolyzed so that a state of GTP $\gamma$ S bound to the G protein-containing cell membrane is maintained. When labeled GTP $\gamma$ S is used, the residual radioactivity on the cell membrane is measured, whereby the receptor

expression cell stimulating activity of a receptor agonist can be assayed. Using this reaction, the stimulating activity of MCH or its derivative on the SLC-1 expression cells can be assayed. This is an assay method using the

5 SLC-1-containing membrane fraction as described in (1) through (3), not using the SLC-1-containing cells as in (4) and (5) described above. According to this method, however, the cell stimulating activity is assayed as in (4) and (5). In this assay system, the substance showing the GTP $\gamma$ S binding

10 promoting activity to the SLC-1 membrane fraction is an agonist. Specifically, the assay is carried out following the procedures of EXAMPLES 9 and 16, which will be later described, as well as their modifications. Herein, the compound that alters the binding property between MCH and

15 SLC-1 can be screened by adding MCH or its derivative or MCH or its derivative and a test compound and monitoring that the GTP $\gamma$ S binding promoting activity to the SLC-1 membrane fraction alters, when compared to administration of MCH or its derivative alone. In this case, the compound

20 that shows suppression of the GTP $\gamma$ S binding promoting activity of the MCH or its derivative to the SLC-1 membrane fraction can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened by administering the test compound

25 alone and monitoring the GTP $\gamma$ S binding promoting activity to the SLC-1 membrane fraction.

An example of the screening method is specifically described below. The cell membrane fraction containing human or rat SLC-1, which is prepared by the procedure described

30 later in EXAMPLE 9 or 16, is diluted with a buffer for membrane dilution (50 mM Tris, 5 mM MgCl<sub>2</sub>, 150 mM NaCl, 1  $\mu$ M GDP, 0.1% BSA, pH 7.4). A degree of dilution varies depending upon the amount of a receptor expressed. The dilution is dispensed by 0.2 ml each in Falcon 2053, to which MCH or

35 its derivative or MCH or its derivative and a test compound

are added. [<sup>35</sup>S]GTPγS is added to the mixture to a final concentration of 200 pM. After maintaining at 25°C for an hour, ice-cooled wash buffer (50 mM Tris, 5 mM MgCl<sub>2</sub>, 150 mM NaCl, 0.1% BSA, 0.05% CHAPS, pH 7.4, 1.5 ml) is added to the mixture followed by filtration through a glass fiber filter paper GF/F. After keeping at 65°C for 30 minutes, the mixture is dried and the radioactivity of [<sup>35</sup>S]GTPγS bound to the membrane fraction remaining on the filter paper is measured with a liquid scintillation counter. When the radioactivity in the experimental group added with MCH or its derivative alone is defined as 100% and the radioactivity in the experimental group added with neither MCH nor its derivative is defined as 0%, an effect of the test compound on the GTPγS binding promoting activity by MCH or its derivative is worked out. The test compound showing the GTPγS binding promoting activity of, for example, 50% or less can be selected as a candidate compound having a competitive inhibitory activity.

(2) In the SLC-1 expression cells, an amount of intracellular cAMP decreases by MCH stimulation. Utilizing this reaction, the stimulating activity of MCH on the SLC-1 expression cells can be assayed.

The amount of cAMP production in various animal cells in which SLC-1 has been expressed can be assayed by RIA using an anti-cAMP antibody, whose antibody is obtained from immunized mouse, rat, rabbit, goat, bovine, etc., and <sup>125</sup>I-labeled cAMP (both commercially available) or by other EIA system using an anti-cAMP antibody and labeled cAMP in combination. Quantification by the SPA technique is also possible, in which beads containing scintillants bearing anti-cAMP antibodies immobilized using protein A or antibodies to IgG, etc. of animal used to produce the anti-cAMP antibodies and <sup>125</sup>I-labeled cAMP are used (a kit manufactured by Amersham Pharmacia Biotech is used).

The inhibition of cAMP production is assayed

specifically by the procedure of EXAMPLE 14 later described or by its modification. In this system, the compound that alters binding of the MCH to the SLC-1 can be screened by increasing the amount of intracellular cAMP by such a ligand as forskolin or calcitonin capable of increasing the amount of intracellular cAMP and monitoring that suppression of the intracellular cAMP production by administration of MCH or its derivative alone is altered by adding MCH or its derivative or MCH or its derivative and a test compound. In this case, the compound that shows an activity of inhibiting the cAMP production inhibitory activity by MCH or its derivative can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, a compound showing an agonist activity can be screened by monitoring the cAMP production inhibitory activity when a test compound alone is added.

The screening method is described below more specifically. CHO/SLC-1 cells are inoculated on a 24-well plate in  $5 \times 10^4$  cells/well followed by cultivation for 48 hours. The cells are washed with Hanks' balanced salt solution (pH 7.4) containing 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES (hereinafter Hanks' balanced salt solution (pH 7.4) containing 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES is referred to as a reaction buffer). Thereafter, 0.5 ml of the reaction buffer is added to the cells and the mixture is kept warm in the medium for 30 minutes. The reaction buffer is removed and 0.25 ml of a fresh reaction buffer is added to the cells. Then, 1 nM MCH or its derivative or 1 nM MCH or its derivative and a test compound is/are added to 0.25 ml of the reaction buffer containing 2  $\mu$ M forskolin. The mixture is added to the cells followed by reacting at 37°C for 24 minutes. The reaction is terminated by adding 100  $\mu$ l of 20% perchloric acid. The reaction mixture is then put on ice for an hour to extract intracellular cAMP.

The amount of cAMP in the extract is measured using a cAMP EIA kit (Amersham Pharmacia Biotech). Taking the amount of cAMP produced by forskolin stimulation as 100% and the amount of cAMP inhibited by the addition of 1 nM MCH or its derivative as 0%, an effect of the test compound on the cAMP production inhibitory activity by MCH or its derivative is calculated. A test compound that inhibits the activity of the MCH or its derivative to reduce the cAMP production activity, e.g., to 50% or more can be selected as a candidate substance having a competitive inhibitory activity.

To determine the cAMP production promoting activity, the amount of cAMP produced by adding a test compound to CHL/SLC-1 cells without adding forskolin is quantified by the procedure described above.

(3) A DNA containing CRE (cAMP response element) is inserted into a multicloning site upstream a luciferase gene in a PicaGene Basic Vector or a PicaGene Enhancer Vector (Toyo Ink Mfg. Co., Ltd.), which is made a CRE-reporter gene vector. In a CRE-reporter gene vector-transfected cell, stimulation associated with increase cAMP induces expression of CRE-mediated luciferase gene and luciferase protein production subsequent thereto. That is, by assaying the luciferase activity, a change in amount of cAMP in the CRE-reporter gene vector transfected cell can be detected. Utilizing the SLC-1-expression cell to which the CRE-reporter gene vector is transfected, a compound that alters the binding between MCH and SLC-1 can be screened. The screening method is specifically described below.

The CRE-reporter gene transfected SLC-1 expression cells are inoculated on a 24-well plate in  $5 \times 10^3$  cells/well followed by cultivation for 48 hours. The cells are washed with Hanks' balanced salt solution (pH 7.4) containing 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES (hereinafter Hanks' balanced salt solution (pH 7.4) containing 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and

In addition to luciferase, alkaline phosphatase, chloramphenicol acetyltransferase or  $\beta$ -galactosidase may be employed as the reporter gene. The enzymatic activity of gene products from these reporter genes can be readily assayed using assay kits commercially available. The alkaline phosphatase activity, the chloramphenicol acetyltransferase activity and the  $\beta$ -galactosidase activity can be assayed, e.g., using Lumi-Phos 530, FAST CAT chloramphenicol acetyltransferase Assay Kit and Aurora

Gal-XE, respectively, all manufactured by Wako Pure Chemical Industries.

(4) The SLC-1 expression cells extracellularly release arachidonic acid metabolites as a result of MCH stimulation. By previously incorporating radioactive arachidonic acid into the cells, the activity can be assayed by measuring the radioactivity released outside the cells. The assay is carried out by the procedure of EXAMPLE 6 later described and its modification. In this case, the compound that affects the arachidonic acid metabolite releasing activity by MCH or its derivative can be screened by adding MCH or its derivative or MCH or its derivative and a test compound and monitoring an effect of the MCH or its derivative on the arachidonic acid metabolite releasing activity. In this case, the compound that inhibits the arachidonic acid metabolite releasing activity by the MCH or its derivative can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, a compound showing an agonist activity can be screened as well by administering a test compound alone and monitoring the arachidonic acid metabolite releasing activity by the SLC-1 expression cells by the procedure modified from EXAMPLE 6 later described. The method for screening a compound that affects the binding between MCH and SLC-1 is described below more specifically.

CHO/SLC-1 cells are inoculated on a 24-well plate in  $5 \times 10^4$  cells/well. After cultivation for 24 hours, [ $^3\text{H}$ ] arachidonic acid is added to the cells in 0.25  $\mu\text{Ci}$ /well. Sixteen hours after the addition of [ $^3\text{H}$ ] arachidonic acid, the cells are washed with Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES. To each well is added 500  $\mu\text{l}$  of a solution obtained by dissolving a 10 nM final concentration of MCH or its derivative or a 10 nM final concentration of MCH or its derivative and a test compound in Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES. Hereinafter Hanks' balanced salt



solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES is referred to as a reaction buffer. After incubating 37°C for 60 minutes, 400 µl of the reaction solution is charged in a scintillator and the amount of [<sup>3</sup>H] arachidonic acid metabolites released in the reaction solution is measured using a scintillation counter. When the amount of [<sup>3</sup>H] arachidonic acid metabolites in the medium of the reaction buffer added with neither MCH nor its derivative is taken as 0% and the amount of [<sup>3</sup>H] arachidonic acid metabolites in the medium added with 10 nM of MCH or its derivative is taken as 100%, an effect of the test compound on the binding between MCH or its derivative and SLC-1 is calculated. The test compound that reduces the arachidonic acid metabolite producing activity, e.g., to 50% or less can be selected as a candidate substance having a competitive inhibitory activity.

(5) When the SLC-1 expression cells are stimulated by MCH, an intracellular Ca level increases. Utilizing such, an effect of a test compound on the binding between MCH and SLC-1 can be monitored.

The SLC-1 expression cells are inoculated on a sterilized cover glass for microscopy. Two days after, the culture medium is replaced by HBSS in which 4 mM Fura-2 AM (Dojin Kagaku Kenkyusho) is suspended, followed by standing at room temperature for 2 hours and 30 minutes. After washing with HBSS, the cover glass is set on a cuvette, and an increased ratio of fluorescence intensity at 505 nm is measured with a fluorescence spectrophotometer at excited wavelengths of 340 nm and 380 nm, when MCH or its derivative or MCH or its derivative and a test compound is/are added. In this case, the compound that affects the binding between MCH and SLC-1 can be screened by measuring a change in fluorescence intensity caused by addition of the test compound, as compared to the case where MCH or its derivative is administered solely. Also, FLIPR (manufactured by Molecular

Device Co.) may be used as described below. That is, Fluo-3 AM (manufactured by Dojin Kagaku Kenkyusho) is added to a cell suspension to incorporate Fluo-3 AM into the cells. The supernatant is washed several times through  
5 centrifugation and the cells are inoculated on a 96-well plate. After setting in the FLIPR device, MCH or its derivative or MCH or its derivative and a test compound is/are added as in Fura-2. The compound that affects the binding between MCH and SLC-1 can be screened by measuring a change  
10 in fluorescence intensity caused by addition of the test compound, as compared to the case where MCH or its derivative is administered solely. In these cases, the compound that inhibits an increase of fluorescence intensity by MCH or its derivative can be selected as a candidate substance  
15 having a competitive inhibitory activity. On the other hand, an agonist can be screened by monitoring an increase of fluorescence intensity when adding the test compound alone.

In the SLC-1 expression cells, when a protein gene such as aequorin that emits light in association with an increase  
20 of intracellular Ca ions is co-expressed and aequorin changes to Ca-bound aequorin by an increase of intracellular Ca ion level to emit light. Utilizing this light emission, the compound that affects the binding between MCH and SLC-1 can be screened by adding MCH or its derivative or MCH or its  
25 derivative and a test compound and, monitoring that light emission observed by addition of the test compound changes, as compared to the case where the MCH or its derivative alone is administered. The method is the same as described above, except that the fluorescent substance is not incorporated  
30 into the cells.

(6) It is known that when a receptor agonist is added to a receptor-expressing cell, a level of intracellular inositol triphosphate increases. By monitoring the reaction in the SLC-1 cells caused by MCH, the compound that affects  
35 the binding between MCH and SLC-1 can be screened. On one

day after inoculation of the cells on a 24-well plate, myo-[2-<sup>3</sup>H]inositol (2.5 microCi/well) is added to each well. In this medium the cells are cultivated for one day. After thoroughly washing, MCH or its derivative or MCH or its derivative and a test compound is/are added to the cells. The reaction is then terminated by adding 10% perchloric acid. The reaction mixture is neutralized with 1.5 M KOH and 60 mM HEPES solution and then passed through a column packed with 0.5 ml of Ag1x8 resin (Bio-Rad). After washing with 5 mM Na<sub>2</sub>BO<sub>3</sub> and 60 mM HCOONH<sub>4</sub>, the radioactivity eluted with 1M HCOONH<sub>4</sub> and 0.1M HCOOH is measured with a liquid scintillation counter. When the radioactivity in the medium of the reaction buffer without adding MCH or its derivative is made 0% and the radioactivity in the medium added with MCH or its derivative is made 100%, an effect of the test compound on the binding between the MCH or its derivative and SLC-1 is calculated. The test compound that inhibits the inositol triphosphate production activity, e.g., to 50% or less can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened as well by monitoring an increase of the inositol triphosphate production activity when adding the test compound alone.

(7) A DNA containing TRE (TPA response element) is inserted into a multicloning site upstream a luciferase gene in a PicaGene Basic Vector or a PicaGene Enhancer Vector (Toyo Ink Mfg. Co., Ltd.), which is made a TRE-reporter gene vector. In a TRE-reporter gene vector-transfected cell, stimulation accompanied by an increase of intracellular Ca induces expression of TRE-mediated luciferase gene and the following luciferase protein production. That is, by assaying the luciferase activity, a change in amount of calcium in the TRE-reporter gene vector transfected cell can be detected. Utilizing the TRE-reporter gene vector-transfected SLC-1 expression cells, a compound that

alters the binding between MCH and SLC-1 can be screened. The screening method is specifically described below.

The TRE-reporter gene-transfected SLC-1 expression cells are inoculated on a 24-well plate in  $5 \times 10^3$  cells/well followed by cultivation for 48 hours. After the cells are washed with Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES, 10 nM of MCH or its derivative or 10 nM of MCH or its derivative and a test compound is/are added to the cells, followed by reacting at  $37^\circ\text{C}$  for 60 minutes. The cells are dissolved in a cell lysis agent for PicaGene (Toyo Ink Mfg. Co., Ltd.) and a luminescence substrate (Toyo Ink Mfg. Co., Ltd.) is added to the lysate. The luminescence by luciferase is measured by a luminometer, a liquid scintillation counter or a top counter. An effect of the compound that alters the binding between MCH and SLC-1 can be measured by comparing the luminescence amount by luciferase with the case when adding MCH or its derivative alone. In this case, the amount of luminescence increases with an increase in intracellular Ca by administration of MCH or its derivative and the compound that suppresses the increase can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened as well by monitoring an increase of luminescence in the same way as in MCH or its derivative, when the test compound alone is administered.

In addition to luciferase, alkaline phosphatase, chloramphenicol acetyltransferase or  $\beta$ -galactosidase may be employed as the reporter gene. The enzymatic activity of gene products from these reporter genes can be easily assayed as described below, using assay kits commercially available. The alkaline phosphatase activity, the chloramphenicol acetyltransferase activity and the  $\beta$ -galactosidase activity can be assayed, e.g., using Lumi-Phos 530, FAST CAT chloramphenicol Acetyltransferase Assay Kit and Aurora Gal-XE, respectively, all manufactured

by Wako Pure Chemical Industries Co., Ltd.

(8) In the SLC-1 expression cells in response to MCH, growth is observed by MAP kinase activation. This growth can be assayed by the MAP kinase activity, thymidine uptake or cell counting (MTT, etc.). Utilizing such, the compound  
5 that alters the binding between the MCH or its derivative and the SLC-1 can be screened.

The MAP kinase activity can be readily assayed by adding MCH or its derivative or MCH or its derivative and a test  
10 compound to the cells, obtaining a MAP kinase fraction from a cell lysate by immunoprecipitation using an anti-MAP kinase antibody and then using, e.g., a MAP Kinase Assay Kit manufactured by Wako Pure Chemical Industries Co., Ltd. and  $\gamma$ -[ $^{32}\text{P}$ ]-ATP. The thymidine uptake activity can be assayed  
15 by inoculating the SLC-1 expression cells, adding MCH or its derivative or MCH or its derivative and a test compound to the cells, further adding [methyl- $^3\text{H}$ ]-thymidine, causing cell lysis and then counting the radioactivity of the labeled thymidine taken up into the cells with a liquid scintillation  
20 counter.

The growth of the SLC-1 expression cells can be determined as well by inoculating the expression cells, adding MCH or its derivative or MCH or its derivative and a test compound, further adding MTT  
25 (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide), taking MTT up into the cells thereby to convert into MTT formazan, causing cell lysis with isopropanol which is rendered acidic with hydrochloric acid, and then measuring absorption at 570 nm.

30 The method for screening the compound that alters the binding between MCH and SLC-1 utilizing the labeled thymidine uptake activity is described below specifically.

The SLC-1 expression cells are inoculated on a 24-well plate in 5000 cells/well followed by incubation for one day.  
35 Next, the cells are incubated in a serum-free medium for

2 days to bring the cells under starvation. MCH or its derivative or MCH or its derivative and a test compound is/are added to the cells. After incubation for 24 hours, [methyl-<sup>3</sup>H] thymidine is added in 0.015 MBq/well followed by incubation  
 5 for 6 hours. After washing the cells with PBS, methanol is added to the cells. The mixture is allowed to stand for 10 minutes. Next, 5% trichloroacetic acid is added and the mixture is allowed to stand for 15 minutes. The immobilized cells are washed 4 times with distilled water. After cell  
 10 lysis with 0.3 N sodium hydroxide solution, the radioactivity in the lysate is measured with a liquid scintillation counter. An effect of the compound that alters the binding between MCH and SLC-1 can be determined by comparing with an increase of the radioactivity by thymidine uptake when MCH or its  
 15 derivative alone is administered. In this case, the compound that suppresses an increase of the radioactivity by administering MCH or its derivative can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened by  
 20 monitoring an increase of the radioactivity in the same way as in the MCH or its derivative when the test compound alone is administered.

(9) When MCH is added to the SLC-1 expression cells, K channel is activated so that K ions present within the  
 25 cells are effluxed extracellularly. Since Rb ions in the related elements to K ions flow out of the cells through the K channel without being distinguished from K ions, labeled Rb ([<sup>86</sup>Rb]) is added to the cells to permit intracellular uptake of the isotope. Then, the efflux of  
 30 [<sup>86</sup>Rb] that flows out by MCH stimulation is measured to assay the action of MCH. The method for screening the compound that alters the binding between MCH and SLC-1 utilizing [<sup>86</sup>Rb] efflux activity is described below specifically.

Two days after inoculation on 24 wells the SLC-1  
 35 expression cells are kept warm for 2 hours in a medium

containing 1 mCi/ml of  $^{86}\text{RbCl}$ . The medium is thoroughly washed to completely remove  $^{86}\text{RbCl}$  in the outer liquid. MCH or its derivative or MCH or its derivative and a test compound are added to the cells. The outer liquid is recovered 30 minutes later and the radioactivity is counted with a  $\gamma$  counter. An effect of the compound that alters the binding between MCH or its derivative and SLC-1 can be assayed by comparing an increase of the radioactivity by [ $^{86}\text{Rb}$ ] efflux with the case when MCH or its derivative alone is administered. In this case, the compound that suppresses an increase of the radioactivity by administration of MCH or its derivative can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened as well by monitoring an increase of the radioactivity in the same way as in the MCH or its derivative when the test compound alone is administered.

(10) The MCH activity can be assayed by measuring extracellular pH (acidification rate) that the SLC-1 expression cells changes in response to MCH, using a Cytosensor device (Molecular Device Co.). The method for screening the compound that alters the binding between MCH and SLC-1 through the extracellular pH measurement using the Cytosensor device is specifically described below.

The SLC-1 expression cells are incubated overnight in a capsule for the Cytosensor device, which is set in a chamber of the device to reflux 0.1% BSA-containing RPMI 1640 medium (manufactured by Molecular Device Co.) until the extracellular pH becomes stable. After the pH becomes stable, a medium containing MCH or its derivative or MCH or its derivative and a test compound is refluxed on the cells to measure a change in pH caused thereby. An effect of the compound that alters the binding between MCH or its derivative and SLC-1 can be assayed by comparing a change of extracellular pH in the SLC-1 expression cells with the case when the MCH or its derivative is administered solely.

In this case, the compound that suppresses a change of extracellular pH in the SLC-1 expression cells by administering MCH or its derivative can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened by monitoring a change of extracellular pH in the same way as in the MCH or its derivative when the test compound alone is administered.

(11) In *Saccharomyces Cerevisiae*, sex pheromone receptor Ste2 of haploid  $\alpha$ -mating type ( $\text{MAT}\alpha$ ) is coupled to G protein Gpa1 to activate MAP kinase in response to sex pheromone  $\alpha$ -mating factor, whereby Far1 (cell-cycle arrest) and transcription activator Ste12 are activated. Ste12 stimulates expression of a wide variety of genes, including FUS1 which is associated with mating. On the other hand, regulator Sst2 functions to inhibit the foregoing process. In this system, an attempt has been made on an assay system for the receptor agonist/receptor reaction, which involves producing a receptor gene-integrated yeast, activating the signal transduction system in yeast cells by receptor agonist stimulation and using the resulting growth, etc. as an index (Pausch, M. H., Trends in Biotechnology, vol. 15, pp. 487-494 (1997)). Utilizing such a receptor gene-integrated yeast system, the compound that alters the binding between MCH and SLC-1 can be screened.

Ste2 in  $\text{MAT}\alpha$  yeast and a gene encoding Gpa1 are removed and instead, SLC-1 gene and a gene encoding Gpa1-Gai2 fused protein are introduced. A gene encoding Far is removed to cause no cell-cycle arrest and a gene encoding Sst is removed to increase the sensitivity in response to MCH. Furthermore, FUS1-HIS3 gene, which is FUS1 ligated with histidine biosynthesis gene HIS3, is introduced. The foregoing genetic recombinant engineering can be easily performed, e.g., by the method reported by Price et al. (Price, L. A. et al., Molecular and Cellular Biology, vol. 15, pp. 6188-6195



The thus produced transformant yeast is incubated overnight in complete synthesis liquid medium and added to a histidine-free soft agar medium in  $2 \times 10^4$  cells/ml, followed by inoculation on a square Petri dish of 9 x 9 cm. After the agar is solidified, a sterilized filter paper impregnated with MCH or its derivative or MCH or its derivative and a test compound is put on the agar surface, followed by incubating at 30°C for 3 days. An effect of the compound that alters the binding between MCH or its derivative and SLC-1 can be assayed by comparing growth of yeast around the filter paper with the case when the MCH or its derivative is administered solely. In this case, the compound that suppresses the growth of yeast by administration of MCH or its derivative can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened as well by monitoring the growth of yeast in the same way as in MCH or its derivative when the test compound alone is administered. Also, the compound that alters the binding between MCH or its derivative and SLC-1 can also be assayed by previously adding the MCH or its derivative to the agar medium, impregnating a sterilized filter paper with a test compound alone, incubating and monitoring that the growth of yeast over the entire surface of the Petri dish is affected

at the periphery of the filter paper.

(12) When the SLC-1 gene RNA is injected into *Xenopus laevis* oocytes are stimulated by MCH, an intracellular Ca ion level increases to cause a calcium-activated chloride current, which can be grasped as fluctuation in membrane potential (same as in the case where fluctuation occurs in a K ion level gradient). By monitoring the above reaction in the SLC-1-introduced *Xenopus laevis* oocytes caused by MCH, the compound that affects the binding between MCH and SLC-1 can be screened.

A female individual of *Xenopus laevis* is anesthetized by immersing in ice water and anatomized for taking out oocytes. The oocyte clusters are treated with collagenase (0.5 mg/ml) dissolved in an MBS solution (88 mM NaCl, 1 mM KCl, 0.41 mM  $\text{CaCl}_2$ , 0.33 mM  $\text{Ca}(\text{NO}_3)_2$ , 0.82 mM  $\text{MgSO}_4$ , 2.4 mM  $\text{NaHCO}_3$ , 10 mM HEPES, pH 7.4) at 19°C for 1 to 6 hours at 150 rpm, until the oocytes are separated one from another. Washing is performed 3 times by replacing the outer liquid by the MBS solution followed by microinjection of poly(A)<sup>+</sup> SLC-1 cRNA (50 ng/50 nl) with a micromanipulator. SLC-1 mRNA may be prepared from tissues or cells or transcribed from plasmids *in vitro*. The oocytes are incubated in the MBS solution at 20°C for 3 days. The oocytes are placed in a hole of a voltage clamp device, which is continuously perfused with Ringer's solution, and impaled with a glass microelectrode for voltage clamp and a glass microelectrodes for recording, in which (-) electrode is placed outside the oocytes. When the holding potential stabilizes, Ringer's solution containing MCH or its derivative or MCH or its derivative and a test compound is perfused to record a change in potential. An effect of the compound that alters the binding between MCH and SLC-1 can be measured by comparing a change in cell membrane potential of the SLC-1-introduced *Xenopus laevis* oocytes with the case when the MCH or its derivative alone is administered. In this case, the compound

that suppresses a change in cell membrane potential caused by administration of the MCH or its derivative can be selected as a candidate substance having a competitive inhibitory activity. On the other hand, an agonist can be screened as well by monitoring the change in cell membrane potential in the same way as in the MCH or its derivative where the test compound alone is administered.

In this system, the amount of alteration may be increased by introducing poly(A)<sup>+</sup> RNAs of various G protein genes so that it becomes easier to monitor the reaction. Also, the reaction can be assayed by co-injecting poly(A)<sup>+</sup> RNAs to a gene of a protein such as aequorin that emits light in the presence of Ca and monitoring the light emission, not a change in membrane potential.

The kits for screening a compound or its salts that alter the binding property between MCH or its salts and SLC-1 or its salts comprises SLC-1 or its salts, SLC-1-containing cells or SLC-1-containing cell membrane fractions and MCH or its derivatives or salts thereof.

The screening kits according to the present invention comprise, for example, the following:

1. Reagents for screening

(1) Buffers for assay and washing

Hanks' Balanced Salt Solution (manufactured by Gibco BRL) supplemented with 0.05% of bovine serum albumin (manufactured by Sigma Co.).

The buffers may be sterilized by filtration through a membrane filter with a 0.45  $\mu$ m pore size and stored at 4°C, or may be prepared at use.

(2) SLC-1 preparation

SLC-1-expressed CHO cells are subcultured at  $5 \times 10^5$  cells/well on a 12-well plate followed by culturing at 37°C under a 5% CO<sub>2</sub> and 95% air for 2 days.

(3) Labeled ligand

MCH labeled with [<sup>3</sup>H], [<sup>125</sup>I], [<sup>14</sup>C], [<sup>35</sup>S], etc. A solution

of the labeled ligand in an appropriate solvent or buffer is stored at 4°C or at -20°C and diluted with a buffer for assay to a concentration of 1 µM.

(4) Standard ligand solution

- 5 MCH is dissolved in PBS containing 0.1% bovine serum albumin (manufactured by Sigma) to yield a concentration of 1 mM, and the solution is stored at -20°C.

2. Method for assay

- (1) The SLC-1-expressed cells cultivated on the 12-well  
10 culture plate are washed twice with 1 ml of the assay buffer, followed by addition of 490 µl of the assay buffer to each well.

- (2) After addition of 5 µl of a  $10^{-3}$  to  $10^{-10}$  M solution of a test compound, 5 µl of the labeled MCH is added followed  
15 by reacting at room temperature for an hour. To determine the amount of the non-specific binding, 5 µl of the ligand (MCH) of  $10^{-3}$  M is added in place of the test compound.

- (3) The reaction mixture is removed and the cells are washed three times with 1 ml each of the buffer for washing.  
20 The labeled ligand (MCH) bound to the cells is dissolved in 0.2N NaOH-1% SDS, and the solution is mixed with 4 ml of a liquid scintillator A (manufactured by Wako Pure Chemical Industries).

- (4) The radioactivity is measured by use of a  
25 scintillation counter (manufactured by Beckman). The percent of the maximum binding (PMB) is calculated from the following equation [Equation 1].

[Equation 1]

30 
$$\text{PMB} = [(B - \text{NSB}) / (B_0 - \text{NSB})] \times 100$$

wherein:

PMB: Percent of the maximum binding

B: Radioactivity when a sample fluid is added

35 NSB: Non-specific binding

B<sub>0</sub>: Maximum binding

The compound or its salt obtainable by the screening method or by the screening kit of the present invention is  
5 the compound that alters (inhibits or promotes) the binding between MCH or its salt and SLC-1 or its salt, specifically a compound or its salts having an SLC-1-mediated cell-stimulating activity (so-called SLC-1 agonists) or a compound having no cell-stimulating activity (so-called  
10 SLC-1 antagonists). Examples of the compound include a peptide, a protein, a non-peptide compound, a synthetic compound, a fermentation product, etc. and the compound may be either novel or known compound.

To determine if the compound is SLC-1 agonists or  
15 antagonists, the following specific procedure (i) or (ii) is available.

(i) The binding assay described in the screening method of (1) through (3) *supra* is performed to obtain the compound that alters the binding property between MCH or its salts  
20 and SLC-1 or its salts (especially inhibits the binding) followed by assay for the compound to determine if the compound has the SLC-1-mediated cell stimulating activities described above. The compound having the cell stimulating activities or its salts are SLC-1 agonists, whereas the  
25 compound having no such activity or its salts are SLC-1 agonists.

(ii) (a) A test compound is brought into contact with SLC-1-containing cells to assay the SLC-1-mediated cell stimulating activities. The compound having the cell  
30 stimulating activities or its salts are SLC-1 agonists.

(b) The SLC-1-mediated cell stimulating activities are assayed both when a compound (e.g., the polypeptide of the present invention or an SLC-1 agonist, etc.) that activates the SLC-1 is brought into contact with the SLC-1-containing  
35 cells and when the compound that activates SLC-1 and a test

compound are brought into contact with the SLC-1-containing cells and comparison is made on the cell stimulating activities between the two cases. The compound or its salts that can reduce the cell stimulating activities by the  
5 SLC-1-activating compound are SLC-1 antagonists.

The SLC-1 agonists exhibit activities similar to the physiological activities that MCH or its salts possess and are thus useful as safe and low toxic drugs as in the MCH or its salts.

10 To the contrary, since the S SLC-1 antagonists can suppress the physiological activities possessed by MCH or its salts, they are useful as safe and low toxic drugs for suppressing the receptor activity.


Since MCH or its salts take part in an appetite (eating)  
15 promoting activity, an oxytocin secretion promoting activity, etc., the MCH or its salts can be used as an appetite (eating) promoting agent, an oxytocin secretion promoting agent, etc. Therefore, in the compounds obtainable using the screening method or screening kit described above, the  
20 SLC-1 agonists are available not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsin, subinvolution of uterus, cesarean section, induced abortion, galactostasis, anorexia such as anorexia nervosa and anemia  
25 accompanied thereby, hypoproteinoses, etc., and the SLC-1 agonists are available not only as an antiobestic agent (drug), an appetite (eating) modulator, etc. but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine  
30 rupture, cervical laceration, preterm delivery, Prader-Willi syndrome, diabetes mellitus and its complications (diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, etc.), hypertension, hyperlipemia, coronary sclerosis, gout, respiratory disease (Pickwick  
35 syndrome, sleep apnea), fatty liver, sterility,

osteoarthritis deformans, etc. (especially an antiobestic agent, an appetite (eating) modulator, etc.).

Specific examples of the compounds obtained using the screening method or the screening kit of the present invention include compounds (1) through (42) below, which are described in, e.g., Japanese Patent Unexamined Publication (Laid-open) No. 11-35788.


(1)

10 N- [2- (N,N-Dimethylamino)methyl-6-tetralinyl] - (4'-methoxybiphenyl-4-yl) carboxamide



15 (2)

4-Benzoyl-N- [2- (N,N-dimethylamino)methyl-6-tetralinyl] benzamide




20

(3)


N- [2- (N,N-Dimethylamino)methyl-6-tetralinyl] -4- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) benzamide

57




(4)

4 - (Benzoylamino) - N - [2 - (N,N-dimethylamino)methyl - 6 - tetra  
5 liny]benzamide



(5)

10 4 - (Benzyloxy) - N - [2 - (N,N-dimethylamino)methyl - 6 - tetralin  
yl]benzamide




15 (6)

N - [2 - (N,N-Dimethylamino)methyl - 6 - tetralinyl] - 9 - oxo - 9H - f  
luorene - 2 - carboxamide






N<sup>1</sup>-[2-(N,N-Dimethylamino)methyl-6-tetralinyl]-N<sup>4</sup>-phenyl  
terephthalamide



5

(11)


(4'-Ethylbiphenyl-4-yl)-N-[2-(N,N-dimethylamino)methyl-  
6-tetralinyl]carboxamide



10

(12)

(4'-Chlorobiphenyl-4-yl)-N-[2-(N,N-dimethylamino)methyl-  
6-tetralinyl]carboxamide




15

(13)

(4'-Acetylamino)phenyl-4-yl)-N-[2-(N,N-dimethylamino)methyl-6-tetralinyl]carboxamide


20

60




(14)

4-(1,3-Benzodioxol-5-yl)-N-[2-(N,N-dimethylamino)methyl  
5 -6-tetralinyl]benzamide




(15)

10 4-Bromo-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]benzamide



15 (16)

3',4'-Dichloro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide




20

(17)


N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-n  
aphthalenyl] -4'-phenyl [1,1'-biphenyl] -4-carboxamide

5 hydrochloride




(18)

10 N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-n  
aphthalenyl] -2'-methoxy[1,1'-biphenyl] -4-carboxamide



15 (19)


N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-n  
aphthalenyl] -4'-oxy[1,1'-biphenyl] -4-carboxamide sodium  
salt



20


(20)

N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-n  
aphthalenyl] -4'-formyl[1,1'-biphenyl] -4-carboxamide



(21)


- 5 N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-naphthalenyl] -4' - (hydroxymethyl) [1,1'-biphenyl] -4-carboxamide



10

(22)

- N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-naphthalenyl] -4' -propyl [1,1'-biphenyl] -4-carboxamide




15

(23)


- 4-Bromo-2-chloro-N- [6- [(N,N-dimethylamino)methyl] -5,6,7,8-tetrahydro-2-naphthalenyl]benzamide

20




(24)

4-Bromo-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-2-methylbenzamide




(25)

4-Bromo-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-3-methylbenzamide



(26)


3,4'-Dichloro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide




20

(27)


4'-Chloro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-3-methyl[1,1'-biphenyl]-4-carboxamide




4'-Chloro-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-2-methyl[1,1'-biphenyl]-4-carboxamide




N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-naphthalenyl] -4' - (trifluoromethyl) [1,1'-biphenyl] -4-carboxamide




N-[6-[(N,N-Dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-4-(3-pyridinyl)benzamide



N-[6-[(N,N-Dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-4'-[(trifluoroacetyl)amino][1,1'-biphenyl]-4-carboxamide




N-[6-[(N,N-Dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-4'-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)[1,1'-biphenyl]-4-carboxamide



4'-Amino-N-[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-2-naphthalenyl][1,1'-biphenyl]-4-carboxamide


20






(34)

N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-n  
aphthalenyl] -4-(2-thienyl)benzamide



(35) Ethyl


4'-[[[6-[(N,N-dimethylamino)methyl]-5,6,7,8-tetrahydro-  
2-naphthalenyl]amino]carbonyl][1,1'-biphenyl]-4-carboxy  
late



(36)


N- [6- [(N,N-Dimethylamino)methyl] -5,6,7,8-tetrahydro-2-n  
aphthalenyl] -4'-(methylsulfonyl) [1,1'-biphenyl] -4-carbo  
xamide

67




(37)

4' - (N,N-Dimethylamino) - N - [6 - [(N,N-dimethylamino)methyl]  
 5 - 5,6,7,8-tetrahydro-2-naphthalenyl] [1,1'-biphenyl] - 4 - ca  
 rboxamide



10 (38)

N - [6 - [(N,N-Dimethylamino)methyl] - 5,6,7,8-tetrahydro-2-n  
 aphthalenyl] - 4' - (methylamino) [1,1'-biphenyl] - 4-carboxam  
 ide




15

(39)


N - [6 - [(N,N-Dimethylamino)methyl] - 5,6,7,8-tetrahydro-2-n  
 aphthalenyl] - 4 - (2-furyl)benzamide

20




(40)

4' - [[ [6 - [(N,N-Dimethylamino)methyl] - 5,6,7,8-tetrahydro-  
2-naphthalenyl] amino] carbonyl] [1,1' - biphenyl] - 4-carboxy  
lic acid



10 (41)


4' - Chloro-N- [6 - [(N,N-dimethylamino)methyl] - 7,8-dihydro-  
2-naphthalenyl] [1,1' - biphenyl] - 4-carboxamide



15

(42)

4' - Fluoro-N- [6 - [(N,N-dimethylamino)methyl] - 7,8-dihydro-  
2-naphthalenyl] [1,1' - biphenyl] - 4-carboxamide



20

The agonist activity of the above-described compound (1)

(N-[2-(N,N-dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide) was measured by the method given in EXAMPLE 21 later described, and the binding inhibition rate (%) was calculated by the equation: (radioactivity when the compound and MCH were added - radioactivity when DMSO solution was added) / (radioactivity when MCH was added - radioactivity when DMSO solution was added) x 100, whereby IC<sub>50</sub> (nM) of the compound was calculated from the binding inhibition rate (%). The IC<sub>50</sub> (nM) of the compound (1) *supra*

(N-[2-(N,N-dimethylamino)methyl-6-tetralinyl]-(4'-methoxybiphenyl-4-yl)carboxamide) was found to be 40. It was thus established that the compound (1) was the compound (antagonist) obtained using the screening method or the screening kit described above.

As the salts of the compounds that are obtainable by the screening method or the screening kit described above, pharmaceutically acceptable salts are employed. Examples of such salts include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids and salts with basic or acidic amino acids, etc.

Preferred examples of the salts with inorganic bases include alkali metal salts such as sodium salts, potassium salts, etc.; alkaline earth metal salts such as calcium salts, magnesium salts, etc.; aluminum salts, ammonium salts, and the like.

Preferred examples of the salts with organic bases include salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc.

Preferred examples of the salts with inorganic acids

Preferred examples of the salts with organic acids include salts with formic acid, acetic acid, propionic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, etc.

10 Preferred examples of the salts with acidic amino acids  
include salts with aspartic acid, glutamic acid, etc.

When the compound or its salts which are obtained by the screening methods or screening kits of the present invention are used as the above-mentioned pharmaceutical compositions, they can be formulated in a conventional manner. For example, they can be administered orally as tablets coated with sugar or with enteric coating if necessary, capsules, elixirs, microcapsules, etc., or parenterally in the form of injections such as sterile solutions or suspensions in water or in pharmaceutically acceptable solutions other than water. For example, the compound or its salts can be mixed with carriers, flavoring agents, excipients, vehicles, preservatives, stabilizers, binders, etc. in a unit dosage form required for generally accepted pharmaceutical practice to prepare pharmaceutical preparations. The amount of active ingredients in these preparations is adjusted so as to obtain appropriate doses within specified ranges.

Additives miscible with tablets, capsules, etc. include  
35 a binder such as gelatin, corn starch, tragacanth and gum

arabic, an excipient such as crystalline cellulose, a swelling agent such as corn starch, gelatin and alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose, lactose and saccharin, and a flavoring agent such as peppermint, akamono oil and cherry. When the unit dosage is in the form of a capsule, liquid carriers such as oils and fats may further be used together with the additives described above. A sterile composition for injection may be formulated in a conventional manner used to make pharmaceutical compositions, e.g., by dissolving or suspending the active ingredients in a vehicle such as water for injection with a naturally occurring vegetable oil such as sesame oil and coconut oil, etc. to prepare the pharmaceutical composition.

Examples of an aqueous medium for injection include physiological saline and an isotonic solution containing glucose and other auxiliary agents (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.) and may be used in combination with an appropriate dissolution aid such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol and polyethyleneglycol), a nonionic surfactant (e.g., polysorbate 80<sup>(TM)</sup> and HCO-50), etc. Examples of the oily medium include sesame oil and soybean oil, which may also be used in combination with a dissolution aid such as benzyl benzoate and benzyl alcohol.

The prophylactic/therapeutic agent described above may further be formulated with a buffer (e.g., phosphate buffer, sodium acetate buffer, etc.), a soothing agent (e.g., benzalkonium chloride, procaine hydrochloride, etc.), a stabilizer (e.g., human serum albumin, polyethyleneglycol, etc.), a preservative (e.g., benzyl alcohol, phenol, etc.), an antioxidant, etc. The thus-prepared liquid for injection is normally filled in an appropriate ampoule.

Since the pharmaceutical preparation thus obtained is safe and low toxic, it can be administered to human or another

mammal (e.g., mouse, rat, guinea pig, rabbit, sheep, swine, bovine, cat, dog, monkey, chimpanzee, etc.).

The dose of the compound or its salts which are obtainable using the screening method or screening kit of the present invention varies depending on conditions, etc.; for example, in oral administration of the compounds, the dose is normally about 0.1 to about 1000 mg, preferably about 1.0 to about 300 mg, more preferably about 3.0 to about 50 mg per day for adult (as 60 kg body weight). In parenteral administration, the single dose varies depending on subject to be administered, target organ, conditions, method for administration, etc.; in the form of an injection, it is advantageous to administer, for example, the SLC-1 antagonist intravenously at a daily dose of about 0.01 to about 30 mg, preferably about 0.1 to about 20 mg, more preferably about 0.1 to about 10 mg for adult (as 60 kg body weight). For other animal species, the corresponding dose as converted per 60 kg weight can be administered.

In the specification and drawings, when bases, amino acids, etc. are represented by abbreviations, the codes for bases and amino acids are denoted in accordance with the IUPAC-IUB Commission on Biochemical Nomenclature or by the codes conventionally used in the art, examples of which are shown below. With respect to amino acids that may have their optical isomers, L form is presented unless otherwise indicated.

	DNA	: deoxyribonucleic acid
	cDNA	: complementary deoxyribonucleic acid
	A	: adenine
30	T	: thymine
	G	: guanine
	C	: cytosine
	Y	: thymine or cytosine
	N	: thymine, cytosine, adenine or guanine
35	R	: adenine or guanine

	M	: cytosine or adenine
	W	: thymine or adenine
	S	: cytosine or guanine
	RNA	: ribonucleic acid
5	mRNA	: messenger ribonucleic acid
	dATP	: deoxyadenosine triphosphate
	dTTP	: deoxythymidine triphosphate
	dGTP	: deoxyguanosine triphosphate
	dCTP	: deoxycytidine triphosphate
10	ATP	: adenosine triphosphate
	EDTA	: ethylenediaminetetraacetic acid
	SDS	: sodium dodecyl sulfate
	TFA	: trifluoroacetic acid
	EIA	: enzyme immunoassay
15	Gly or G	: glycine
	Ala or A	: alanine
	Val or V	: valine
	Leu or L	: leucine
	Ile or I	: isoleucine
20	Ser or S	: serine
	Thr or T	: threonine
	Cys or C	: cysteine
	Met or M	: methionine
	Glu or E	: glutamic acid
25	Asp or D	: aspartic acid
	Lys or K	: lysine
	Arg or R	: arginine
	His or H	: histidine
	Phe or F	: phenylalanine
30	Tyr or Y	: tyrosine
	Trp or W	: tryptophan
	Pro or P	: proline
	Asn or N	: asparagine
	Gln of Q	: glutamine
35	pGlu	: pyroglutamic acid



	Me	: methyl group
	Et	: ethyl group
	Bu	: butyl group
	Ph	: phenyl group
5	Tc	: thiazolidine-4(R)-carboxamide group
	Bom	: benzyloxymethyl
	NMP	: N-methylpyrrolidone
	PAM	: phenylacetamidomethyl

10       The substituents, protecting groups and reagents which are frequently used in the present specification are represented by the following symbols.

	Tos	: p-toluenesulfonyl
15	HONB	: N-hydroxy-5-norbornene-2,3-dicarboximide
	Bzl	: benzyl
	Z	: benzyloxycarbonyl
	Br-Z	: 2-bromobenzyloxycarbonyl
	Cl-Z	: 2-chlorobenzyloxycarbonyl
20	Boc	: t-butoxycarbonyl
	HOBt	: 1-hydroxybenztriazole
	DCC	: N,N'-dichlorohexylcarbodiimide
	TFA	: trifluoroacetic acid
	Fmoc	: N-9-fluorenylmethoxycarbonyl
25	DNP	: dinitrophenol
	Bom	: t-butoxymethyl
	Trt	: trityl
	BSA	: bovine serum albumin
	CHAPS	:
30		3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
	PMSF	: phenylmethylsulfonyl fluoride
	E64	: (L-3-trans-carboxirane-2-carbonyl)
		L-leucyl-agmatine
35	GDP	: guanosine-5'-diphosphate

MEMα : minimum essential medium alpha  
 Fura-2AM: pentacetoxymethyl  
           1-[6-amino-2-(5-carboxy-2-oxazolyl)-5-benzofur  
           anyloxy]-2-(2-amino-5-methylphenoxy)ethane-N,N  
 5           ,N',N'-tetraacetate  
 HBSS : Hanks' balanced salt solution  
 Fluo-3AM: pentacetoxymethyl  
           1-[2-amino-5-(2,7-dichloro-6-hydroxy-3-oxy-9-x  
           anthenyl)phenoxy]-2-(2-amino-5-methylphenoxy)e  
 10           thane-N,N,N',N'-tetraacetate  
 HEPES :  
           2-[4-(2-hydroxyethyl)-1-piperaziny]-ethanesul  
           fonic acid  
 MeBzl : 4-methylbenzyl  
 15       NMP : N-methylpyrrolidone

The sequence identification numbers in the sequence  
 listing of the specification indicate the following  
 sequences.

20 [SEQ ID NO: 1]

This represents an amino acid sequence obtained from  
 N-terminal amino acid sequence analysis of a ligand peptide  
 to the SLC-1 purified from rat brain.

[SEQ ID NO: 2]

25 This represents an amino acid sequence of a ligand  
 peptide to the SLC-1 purified from rat brain, which is  
 identified to be rat MCH.

[SEQ ID NO: 3]

This represents a synthetic DNA used to screen cDNA  
 30 encoding rat SLC-1.

[SEQ ID NO: 4]

This represents a synthetic DNA used to screen cDNA  
 encoding rat SLC-1.

[SEQ ID NO: 5]

35 This represents the full-length amino acid sequence

of rat SLC-1.

[SEQ ID NO: 6]

This represents the full-length base sequence of rat SLC-1 cDNA in which Sal I recognition sequence is added at the 5' side and Spe I recognition sequence at the 3' side.

[SEQ ID NO: 7]

This represents a riboprobe used to measure the amount of SLC-1 mRNA expressed in each clone of rat SLC-1-expressed CHO cells.

[SEQ ID NO: 8]

This represents a synthetic DNA used to acquire cDNA encoding human SLC-1.

[SEQ ID NO: 9]

This represents a primer used to convert cDNA encoding human SLC-1 into double strands.

[SEQ ID NO: 10]

This represents the full-length base sequence of cDNA encoding human SLC-1.

[SEQ ID NO: 11]

This represents the full-length amino acid sequence of human SLC-1.

[SEQ ID NO: 12]

This represents a synthetic DNA used to screen cDNA encoding human SLC-1(S).

[SEQ ID NO: 13]

This represents a synthetic DNA used to screen cDNA encoding human SLC-1(S).

[SEQ ID NO: 14]

This represents a synthetic DNA used to screen cDNA encoding human SLC-1(L).

[SEQ ID NO: 15]

This represents a synthetic DNA used to screen cDNA encoding human SLC-1(L).

[SEQ ID NO: 16]

This represents the full-length base sequence of human

SLC-1(S) cDNA in which Sal I recognition sequence is added at the 5' side and Spe I recognition sequence at the 3' side.  
[SEQ ID NO: 17]

5 This represents the full-length base sequence of human SLC-1(L) cDNA in which Sal I recognition sequence is added at the 5' side and Spe I recognition sequence at the 3' side.  
[SEQ ID NO: 18]

This represents a riboprobe used to measure the amount of SLC-1 mRNA expressed in each clone of human  
10 SLC-1(S)-expressed CHO cells and human SLC-1(L)-expressed CHO cells.  
[SEQ ID NO: 19]

This represents an amino acid sequence of Des-Asp<sup>1</sup>-MCH (MCH(2-19)).  
15 [SEQ ID NO: 20]

This represents an amino acid sequence of Des-[Asp<sup>1</sup>, Phe<sup>2</sup>]-MCH (MCH(3-19)).  
[SEQ ID NO: 21]

This represents an amino acid sequence of Des-[Asp<sup>1</sup>, Phe<sup>2</sup>, Asp<sup>3</sup>]-MCH (MCH(4-19)).  
20 [SEQ ID NO: 22]

This represents an amino acid sequence of Des-[Asp<sup>1</sup>, Phe<sup>2</sup>, Asp<sup>3</sup>, Met<sup>4</sup>]-MCH (MCH(5-19)).  
[SEQ ID NO: 23]

25 This represents an amino acid sequence of Des-[Asp<sup>1</sup>, Phe<sup>2</sup>, Asp<sup>3</sup>, Met<sup>4</sup>, Leu<sup>5</sup>]-MCH (MCH(6-19)).  
[SEQ ID NO: 24]

This represents an amino acid sequence of Des-[Asp<sup>1</sup>, Phe<sup>2</sup>, Asp<sup>3</sup>, Met<sup>4</sup>, Leu<sup>5</sup>, Arg<sup>6</sup>]-MCH (MCH(7-19)).

30

Transformant *Escherichia coli* DH10B/phSLC1L8 transformed with plasmid containing a DNA coding for the base sequence shown by SEQ ID NO:11, which was obtained in EXAMPLE 8, was on deposit with the Ministry of International  
35 Trade and Industry, Agency of Industrial Science and

Technology, National Institute of Bioscience and Human  
Technology (NIBH) as Accession Number FERM BP-6632 on  
February 1, 1999 and with Institute for Fermentation, Osaka  
(IFO) as Accession Number IFO 16254 on January 21, 1999.

5

#### EXAMPLES

The present invention is described below in more detail  
with reference to EXAMPLES and REFERENCE EXAMPLES, but not  
intended to limit the scope of the present invention thereto.

10

REFERENCE EXAMPLE 1 Detection of the activity contained in  
rat brain extract and specifically inhibiting cAMP synthesis  
of CHO/SLC-1 cells

Fractions of the rat brain extract by high performance  
15 liquid chromatography (HPLC) were prepared by the method  
described below. Brains were withdrawn from 100 Wistar rats  
(male, 8 weeks old) purchased from Charles River Co. and  
immediately put into 0.8 liter of boiling distilled water  
followed by boiling for 10 minutes. Immediately after the  
20 boiling, the brains were ice-cooled and 48 ml of acetic acid  
was added thereto to a final concentration of 1.0 M. Using  
a polytron (20,000 rpm, 6 mins.), the cells were disrupted.  
The cell disruption fluid was centrifuged (8,000 rpm, 30  
mins.). The supernatant was taken out and to the precipitate,  
25 0.8 liter of 1.0 M acetic acid was added. The cells were  
again disrupted by the polytron followed by centrifugation  
(8,000 rpm, 30 mins.). The supernatant was thus obtained.  
After 0.8 liter of 1.0 M acetic acid was added to the  
precipitate, the mixture was again disrupted by the polytron.  
30 After stirring overnight, centrifugation was performed  
(8,000 rpm, 30 mins.) to obtain the supernatant. After 2-fold  
volume of chilled acetone was dropwise added slowly to the  
supernatant at 4°C, the supernatant obtained by the first  
centrifugation was stirred overnight and, the supernatant  
35 obtained by the second centrifugation was stirred for 4 hours.

The acetone-added extract was centrifuged (8,000 rpm, 30 mins.) to remove the precipitate. Acetone was evaporated off in vacuum from the supernatant obtained, using an evaporator. After an equal volume of diethyl ether was added to the acetone-free extract, the ethereal layer containing lipids was separated using a separating funnel to recover the aqueous layer. The lipids were removed with ether and the extract was concentrated in vacuum using an evaporator to completely remove the ether. The concentrate was filtrated through a glass fiber filter paper (Advantech, DP70 (90 mm $\phi$ )) and the filtrate was charged in a glass-made column (20 mm $\phi$  x 240 mm) packed with C18 (YMC, YMCgel ODS-AM120-S50). After washing with 300 ml of 1.0 M acetic acid, the column was eluted with 300 ml of 60% acetonitrile containing 0.1% trifluoroacetic acid. The eluate was concentrated in vacuum to distill the solvent off. The concentrate was then lyophilized. About 0.24 g of the lyophilized product was dissolved in 5 ml of DMSO and then, 45 ml of 1.0 M acetic acid was added to the solution to prepare the rat brain extract preparation. The rat brain extract preparation was passed through an SP-Sephadex C-25 column (Amersham Pharmacia Biotech, gel volume: 100 ml) which had been equilibrated with 1.0 M acetic acid. After washing with 50 ml of 1.0 M acetic acid, a fraction eluted with 100 ml of 2.0 M pyridine and a fraction eluted with 100 ml of 2.0 M pyridine/acetic acid were obtained sequentially. The 2.0 M pyridine/acetic acid eluate was concentrated in vacuum to distill the solvent off, the concentrate was lyophilized. About 100 mg of the lyophilized product was dissolved in 10 ml of 10% acetonitrile containing 0.1% trifluoroacetic acid. The solution was applied to HPLC by acetonitrile density gradient elution of 10% to 60% acetonitrile containing 0.1% trifluoroacetic acid, using a C18 column (TOSO, TSKgel ODS-80T<sub>8</sub> (21.5 mm $\phi$  x 300 mm)). Each fraction was concentrated and evaporated to dryness in vacuum. The residue was

dissolved in 0.2 ml of dimethylsulfoxide (DMSO).

The CHO/SLC-1 cells prepared in EXAMPLE 4 and mock CHO cells were inoculated on a 24-well plate in  $5 \times 10^4$  cells/well. After incubation for 48 hours, the cells were washed with  
5 Hanks' balanced salt solution (pH 7.4) supplemented with 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES (hereinafter Hanks' balanced salt solution (pH 7.4) supplemented with 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES is referred to as a reaction buffer).  
10 Thereafter, 0.5 ml of the reaction buffer was added to the cells, which was kept warm in the medium for 30 minutes. The reaction buffer was removed and 0.25 ml of a fresh reaction buffer was added to the cells. Then, 0.25 ml of the reaction buffer containing the HPLC fraction and 2  $\mu$ M forskolin was  
15 added to the cells followed by reacting at 37°C for 24 minutes. By adding 100  $\mu$ l of 20% perchloric acid, the reaction was terminated. The reaction mixture was then allowed to stand on ice for an hour to extract intracellular cAMP. The amount of cAMP in the extract was measured using a cAMP EIA kit  
20 (Amersham Pharmacia Biotech). As a result, the cAMP synthesis inhibitory activity specific to the CHO/SLC-1 cells was detected in fractions #33, #34 and #35 (FIG. 1). In FIG. 1, taking as 100% the amount obtained by subtracting the intracellular cAMP amount when adding the reaction buffer  
25 from the intracellular cAMP amount when adding the forskolin-containing reaction buffer, the cAMP synthesis inhibitory activity was expressed by % in terms of the intracellular cAMP amount obtained by subtracting the intracellular cAMP amount when adding the reaction buffer  
30 from the intracellular cAMP amount when adding the HPLC fraction (a 1  $\mu$ l aliquot of each fraction diluted to 100-fold with DMSO was added).

REFERENCE EXAMPLE 2 Inactivation with pronase of the active  
35 substance showing the cAMP synthesis inhibitory activity

specific to the SLC-1-expressed CHO cells in the rat brain extract

The HPLC fraction #34 found to have the cAMP synthesis inhibitory activity on the CHO/SLC-1 cells in REFERENCE  
5 EXAMPLE 1 was treated with a pronase (Sigma, protease Type XIV (P5147)), which is a proteolytic enzyme to examine if the active substance is proteinaceous.

The HPLC fraction (#34), 2  $\mu$ l, from the rat brain extract described above was added to 100  $\mu$ l of 0.2 M ammonium acetate  
10 and 3  $\mu$ g of pronase was added to the mixture. After incubating at 37°C for 2 hours, the reaction mixture was boiled in boiling water for 10 minutes to inactivate the pronase. To the reaction solution was added 2 ml of distilled water containing 0.05 mg of BSA and 0.05 mg of CHAPS, followed  
15 by lyophilization. In order to examine if pronase itself, or heating and lyophilization have any effect on the test, pronase alone, the HPLC fraction alone, and a mixture of the HPLC fraction and pronase, which pronase alone was heated, were treated and lyophilized in a similar manner. Each sample  
20 fluid thus lyophilized was dissolved in a reaction buffer containing 2  $\mu$ M forskolin. Each solution was added to the CHO/SLC-1 cells by the procedures described in REFERENCE EXAMPLE 1 and the cAMP synthesis inhibitory activity was assayed. The results are shown in FIG. 2. Since the active  
25 substance showing the cAMP synthesis inhibitory activity against the CHO/SLC-1 cells in the rat brain extract were completely inactivated, the substance was found to be a protein or peptide.

30 REFERENCE EXAMPLE 3 Purification of the active substance showing the cAMP synthesis inhibitory activity specific to the rat SLC-1/CHO cells from rat brain

A representative example of purifying from rat brain the active substance showing the cAMP synthesis inhibitory  
35 activity specifically to the SLC-1/CHO cells is concretely



described below.

The fraction #33 which was found to be effective in REFERENCE EXAMPLE 1 was purified as follows. After the active fraction was concentrated in vacuum to remove the solvent, the concentrate was lyophilized. The lyophilized active substance was dissolved in 5 ml of 10 mM ammonium formate (pH 5.25) containing 10% acetonitrile. The solution was passed through a cationic exchange column (TOSO, TSKgel CM-2SW (4.6 mmφ x 150 mm)). Subsequently, the column was eluted by density gradient of 10 mM to 500 mM ammonium formate (pH 5.25) containing 10% acetonitrile. The activity was recovered around 320 mM ammonium formate. To 2 ml of the active fraction was added 2.5 ml of 10% acetonitrile containing 0.1% trifluoroacetic acid. After the mixture was passed through a diphenyl column (Separation Group, Vydac 219-TP54), elution was performed by density gradient of 27.5% to 42.5% acetonitrile containing 0.1% trifluoroacetic acid. The activity appeared around 31.3% acetonitrile. After 4.4 ml of 10% acetonitrile containing 0.1% trifluoroacetic acid was added to 0.96 ml of the active fraction, the mixture was passed through an ODS column (Nomura Kagaku, Develosil ODS-UG-3), elution was performed by density gradient of 27.5% to 42.5% acetonitrile containing 0.1% trifluoroacetic acid. The eluate was manually fractionated for every peak. The activity appeared around 36.8% acetonitrile (fraction No. 16) as a single peak (FIG. 3).

REFERENCE EXAMPLE 4 Identification of the active substances to be a rat MCH, showing the cAMP synthesis inhibitory activity specifically to rat SLC-1-expressed CHO cells purified from rat brain

The active substance showing the cAMP synthesis inhibitory activity specifically to the rat SLC-1-expressed CHO cells which was purified in REFERENCE EXAMPLE 3 was subjected to structural analysis. Since it was speculated



as to amplify genes at the region to be translated into  
receptor proteins. In this case, recognition sequences of  
the respective restriction enzymes were added at the 5' and  
3' sides so that the base sequence recognized by restriction  
enzyme Sal I was added at the 5' side of the gene and the  
5 base sequence recognized by restriction enzyme Spe I at the  
3' side. The reaction solution was composed of 5  $\mu$ l of the  
cDNA template, 0.4  $\mu$ M each of the synthetic DNA primers,  
0.25 mM dNTPs, 0.5  $\mu$ l of pfu (Stratagene Co.) DNA polymerase  
10 and a buffer attached to the enzyme, which were mixed together  
to make the total volume 50  $\mu$ l. Using a Thermal Cycler  
(Perkin-Elmer Co.) for amplification, heating at 94°C for  
60 seconds was followed by repeating 35 times a cycle set  
to include 94°C for 60 seconds, 60°C for 30 seconds and 72°C  
15 for 150 seconds, and finally reacting at 72°C for 10 minutes.  
The amplified product was confirmed by 0.8% agarose gel  
electrophoresis followed by staining with ethidium bromide.

EXAMPLE 2 Subcloning of the PCR product into a plasmid vector  
20 and confirmation of the amplified cDNA sequence by decoding  
a base sequence of the inserted cDNA part

The PCR product obtained by PCR in EXAMPLE 1 was separated  
by using a 0.8% low melting point agarose gel. The band part  
was excised from the gel with a razor blade, cut into small  
25 pieces, extracted with phenol and then with  
phenol/chloroform and precipitated in ethanol to recover  
DNAs. According to the protocol attached to PCR-Script™  
Amp SK(+) Cloning Kit (Stratagene Co.), the recovered DNAs  
were subcloned to plasmid vector pCR-Script Amp SK(+). The  
30 recombinant vector was introduced into *Escherichia coli* XL-1  
Blue (Stratagene Co.) to produce transformants. The clones  
having a cDNA-inserted fragment were selected in an LB agar  
medium containing ampicillin and X-gal. Only the clones  
exhibiting white color were picked up with a sterilized  
35 toothpick to obtain transformant *E. coli* XL-1 Blue/rat SLC-1.

The individual clones were cultured overnight in an LB medium containing ampicillin. Plasmid DNAs were prepared using QIA prep8 mini prep (Qiagen Co.). An aliquot of the DNAs thus prepared was cleaved by restriction enzymes Sal I and Spe I to confirm the size of the receptor cDNA fragment inserted. The reaction for base sequencing was carried out by using a DyeDeoxy Terminator Cycle Sequence Kit (Perkin-Elmer Co.), followed by decoding with a fluorescent automatic sequencer. It was confirmed by sequence analysis that the sequences of 3 clones obtained was in agreement with the gene sequence in the cDNA sequence (Lakaye, B. et al., Biochim. Biophys. Acta, Vol. 1401, pp. 216-220 (1998), accession No. AF08650) encoding rat SLC-1 protein (SEQ ID NO:5) with the full-length sequence reported, wherein the Sal I recognition sequence was added at the 5' side and the Spe I recognition sequence was added at the 3' side (SEQ ID NO:6).

EXAMPLE 3 Preparation of rat SLC-1-expression CHO cells  
Using Plasmid Midi Kit (Qiagen Co.), plasmid was prepared from clones of *E. coli* transformed by the plasmid encoding the full-length amino acid sequence of the rat brain-derived SLC-1, which sequence was confirmed in EXAMPLE 2, with the Sal I recognition sequence added at the 5' side and with the Spe I recognition sequence added at the 3' side. The plasmid was cleaved with restriction enzymes Sal I and Spe I to excise the insert part out. After electrophoresis, the inserted DNA was excised from the agarose gel with a razor blade, cut into small pieces and extracted with phenol and then with phenol/chloroform, followed by precipitation in ethanol to recover the inserted DNA. The inserted DNA was added to Sal I- and Spe I-cleaved vector plasmid pAKK0-111H for animal cell expression (same as the vector plasmid pAKK01.11H described in Hinuma, S. et al., Biochim. Biophys. Acta, Vol. 1219, pp. 251-259 (1994)) followed by ligation using T4 ligase (Takara Shuzo Co.). Thus, plasmid

pAKK0-SLC-1 for protein expression was constructed.

After *E. coli* DH5 (Toyobo Co.) transformed by pAKK0-SLC-1 was cultured, plasmid DNA of pAKK0-SLC-1 was prepared using Plasmid Midi Kit (Qiagen Co.). Using CellPfect Transfection Kit (Amersham Pharmacia Biotech Co.), the plasmid DNA was introduced into CHO dhfr<sup>r</sup> cells, according to the protocol attached to the Kit. DNA, 10 µg, was co-precipitated with calcium phosphate in suspension. The suspension was added to a 10 cm Petri dish on which  $5 \times 10^5$  or  $1 \times 10^6$  CHO dhfr<sup>r</sup> cells had been inoculated before 24 hours. The cells were cultured in MEMα medium containing 10% calf fetal serum for one day. After passage, the cells were cultured in nucleic acid-free MEMα medium for selection containing 10% dialyzed calf fetal serum and 56 clones of the transformant SLC-1-expression CHO cells were selected as those growing in the selection medium.

EXAMPLE 4 Selection of the CHO/SLC-1 cell line with high expression of the full-length rat SLC-1 receptor protein mRNA

The expression amounts of the full-length rat SLC-1 receptor protein mRNAs of 56 clones from the CHO/SLC-1 strain established in EXAMPLE 3 were measured as follows, using a Cytostar T Plate (Amersham Pharmacia Biotech Co.), in accordance with the protocol attached. Each clone of the CHO/SLC-1 strain was inoculated on a Cytostar T Plate in  $2.5 \times 10^4$  cells/well, respectively. After culturing for 24 hours, the cells were fixed with 10% formalin. After 0.25% Triton X-100 was added to each well to increase the cell permeability, <sup>35</sup>S-labeled riboprobe of SEQ ID NO:7 was added to the cells for hybridization. By adding 20 mg/ml of RNaseA to each well, free riboprobe was digested. After the plate was thoroughly washed, radioactivity of the riboprobe hybridized was assayed with a Topcounter. The strain with a high radioactivity provides a high expression amount of

mRNA. Three clones (#3, #6 and #44) which showed a high expression amount of mRNA were used for the following experiment, especially clone #44 as a main clone (FIG. 4).

5 EXAMPLE 5 cAMP synthesis inhibitory activity of MCH on rat SLC-1-expression CHO cells

The synthetic MCH (Peninsula Co.) was diluted in various concentrations and the cAMP synthesis inhibitory activity was assayed on the rat SLC-1-expression CHO cells by the following method. The CHO/SLC-1 cells selected in EXAMPLE 10 4 were inoculated on a 24-well plate in  $5 \times 10^4$  cells/well followed by cultivation for 48 hours. The cells were then washed with Hanks' balanced salt solution (pH 7.4) containing 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES 15 (hereinafter Hanks' balanced salt solution (pH 7.4) containing 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES is referred to as a reaction buffer). Subsequently, 0.5 ml of the reaction buffer was added to the cells, which was kept in the medium for 30 minutes. The reaction buffer 20 was removed and 0.25 ml of a fresh reaction buffer was added to the cells. Then, 0.25 ml of the reaction buffer containing various amounts of MCH and 2  $\mu$ M forskolin was added to the cells followed by reacting at 37°C for 24 minutes. By adding 100  $\mu$ l of 20% perchloric acid, the reaction was terminated. 25 The reaction mixture was then allowed to stand on ice for an hour to extract intracellular cAMP. The amount of cAMP in the extract was measured using cAMP EIA kit (Amersham Pharmacia Biotech). The results reveal that MCH obviously reduced the amount of intracellular cAMP in the concentration 30 of 0.1 nM. When the peptide concentration increased, the amount of intracellular cAMP decreased dose-dependently (FIG. 5). In FIG. 5, taking as 100% the amount obtained by subtracting the intracellular cAMP amount when adding the reaction buffer from the intracellular cAMP amount when 35 adding the forskolin-containing reaction buffer, the cAMP

synthesis inhibitory activity was expressed by % in terms of the intracellular cAMP amount obtained by subtracting the intracellular cAMP amount when adding the reaction buffer from the intracellular cAMP amount when adding MCH.

5  
EXAMPLE 6 Arachidonic acid metabolite release activity induced by MCH on rat SLC-1-expression CHO cells

The arachidonic acid metabolite release activity of the synthetic MCH (Peninsula Co.) in various concentrations  
10 on rat SLC-1-expression CHO cells was assayed by the following method. The CHO/SLC-1 cells selected in EXAMPLE 4 were inoculated on a 24-well plate in  $5 \times 10^4$  cells/well. After incubation for 24 hours, [ $^3\text{H}$ ] arachidonic acid was added to each well in 0.25  $\mu\text{Ci}$ /well. Sixteen hours after  
15 the addition of [ $^3\text{H}$ ] arachidonic acid, the cells were washed with Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES. Then, 500  $\mu\text{l}$  of solutions in various concentrations of the synthetic rat MCH dissolved in Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and  
20 20 mM HEPES was added to each well. Hereinafter Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES is referred to as a reaction buffer. After incubating at  $37^\circ\text{C}$  for 60 minutes, 400  $\mu\text{l}$  of the reaction solution was charged in a scintillator and the amount of  
25 [ $^3\text{H}$ ] arachidonic acid metabolites released into the reaction solution was measured using a scintillation counter. Apparent release of arachidonic acid metabolites occurred with 3 nM of the synthetic rat MCH and when the peptide concentration was further increased, the arachidonic acid  
30 metabolites were dose-dependently released into the medium (FIG. 6). In FIG. 6, the arachidonic acid metabolite release activity was expressed in terms of a relative amount of the [ $^3\text{H}$ ] arachidonic acid metabolites in the medium when the synthetic rat MCH was added to the reaction buffer, when  
35 the amount of the [ $^3\text{H}$ ] arachidonic acid metabolites in the

reaction buffer added with no synthetic rat MCH was taken as 100%.

EXAMPLE 7 Isolation of plasmid containing human SLC-1 cDNA

5        Using a human fetal brain-derived cDNA library (SUPERScript™ cDNA Library, GIBCO BRL), DNA was nicked using phage F1 endonuclease followed by digesting with *Escherichia coli* exonuclease III, in accordance with the manual of GenetrappercDNA positive selection system (GIBCO BRL). Thus, 10 a single stranded human fetal brain cDNA library was prepared.

      Based on the report by Kolakowski Jr., et al. (Kolakowski Jr., et al. (1996) FEBS Lett. Vol. 398, pp. 253-258), the synthetic oligonucleotide shown by SEQ ID NO:8 (which 15 corresponds to 1434-1451 of accession No. U71092) was prepared. Using a Terminal Deoxynucleotidyl Transferase, biotin-14-dCTP was added to the synthetic oligonucleotide at the 3' end to prepare biotinylated oligonucleotide. The composition of the reaction solution and the reaction time 20 were set as instructed by the manual.

      After 4 µg of the single stranded human fetal brain-derived cDNA library was maintained at 95°C for a minute, the cDNA library was quenched on ice and 20 ng of the biotinylated oligonucleotide was added thereto followed 25 by hybridizing at 37°C for an hour in a hybridization buffer attached. After adding strepto-avidin beads, the single stranded human fetal brain-derived cDNA hybridized to the biotinylated oligonucleotide was isolated using MAGNA-SEP Magnetic Particle Separator (GIBCO BRL). Using as a primer 30 50 ng of the synthetic oligonucleotide shown by SEQ ID NO:9 (which corresponds to 1011-1028 of accession No. U71092) prepared based on the report by Kolakowski Jr. et al. (Kolakowski Jr., et al. (1996) FEBS Lett. Vol. 398, pp. 253-258), the complementary strand was prepared according 35 to the manual, which was made a double stranded plasmid.



EXAMPLE 8 Determination of a base sequence of the isolated plasmid containing the human SLC-1 cDNA

The plasmid obtained in EXAMPLE 7 was introduced into  
5 ELECTROMAX™ DH10B™ cells for transformation by electroporation. The clones having a cDNA-inserted fragment were selected in an LB agar medium supplemented with ampicillin and X-gal. Only the clones exhibiting white color were separated from one another by picking at the clones  
10 with a sterilized toothpick to obtain transformant *E. coli* DH10B/hSLC-1. The individual clones were cultured overnight in an LB medium containing ampicillin and plasmid DNAs were purified using QIAprep8 mini prep (Qiagen Co.). The reaction for base sequencing was carried out by using a DyeDeoxy  
15 Terminator Cycle Sequence Kit (Perkin-Elmer Co.), followed by decoding with a fluorescent automatic sequencer. Thus, the sequence shown by SEQ ID NO:10 was obtained. The amino acid sequence (SEQ ID NO:11) encoded by the base sequence obtained here is different from the putative human SLC-1  
20 amino acid sequence as a sequence deduced from the rat SLC-1 reported by Lakaye et al. (Lakaye, B. et al., (1998) Biochem. Biophys. Acta, Vol. 1401, pp. 216-220), based on the human chromosomal DNA sequence containing the human SLC-1 sequence (accession No. Z86090), indicating that initiation codon  
25 ATG is present on mRNA further upstream the 69th and 64th amino acids of the putative sequence. Transformant *Escherichia coli* DH10B/phSLC1L8 by the plasmid bearing a DNA encoding this sequence was on deposit with IFO and NIBH.

30 EXAMPLE 9 Assay for GTPγS binding activity to a rat SLC-1-expression CHO cell membrane fraction induced by MCH

The binding promoting activity of [<sup>35</sup>S]-guanosine 5'-(γ-thio)triphosphate by MCH to an SLC-1-expression CHO cell membrane fraction was assayed by the following method.  
35 First, preparation of the membrane fraction is described.

To  $1 \times 10^8$  CHO/SLC-1 cells was added 10 ml of a homogenate buffer (10 mM NaHCO<sub>3</sub>, 5 mM EDTA, 0.5 mM PMSF, 1 µg/ml pepstatin, 4 µg/ml E64, 20 µg/ml leupeptin), followed by cell disruption with a polytron (12,000 rpm, 1 min.). The disrupted cells were then centrifuged (1,000 g, 15 mins.) to give the supernatant. Next, the supernatant was subjected to ultracentrifugation (Beckman type 30 rotor, 30,000 rpm, 1 hour). The resulting precipitate was used as a rat SLC-1-expression CHO cell membrane.

10 The GTPγS binding activity was assayed as follows. The rat SLC-1-expression CHO cell membrane fraction was diluted with a buffer for membrane dilution (50 mM Tris-hydrochloride buffer (pH 7.4), 5 mM MgCl<sub>2</sub>, 150 mM NaCl, 1 µM GDP) to make a cell membrane fraction solution for assay having a protein concentration of 30 mg/ml. To 200 µl of the cell membrane fraction solution for assay were added 2 µl of 51.5 nM [<sup>35</sup>S]-guanosine 5'-(γ-thio)triphosphate (NEN Co.) and 2 µl of MCH (Peninsula Co.) in various concentrations. The resulting solution mixture was kept at 25°C for an hour.

20 The mixture was filtrated through a filter. After washing twice with 1.5 ml of a washing buffer (50 mM Tris-hydrochloride buffer (pH 7.4), 5 mM MgCl<sub>2</sub>, 1 mM EDTA, 0.1% BSA), radioactivity of the filter was measured using a liquid scintillation counter. The MCH dose-dependently increased the amount of [<sup>35</sup>S]-guanosine

25 5'-(γ-thio)triphosphate bound to the membrane fraction. The MCH in a concentration of about 0.5 nM induced 50% binding which was the total binding.

#### 30 EXAMPLE 10 Amplification of human SLC-1 cDNA by PCR using human fetal brain-derived cDNA

Using as a template a plasmid containing human SLC-1 DNA sequence cloned by gene trap, amplification by PCR was performed using the synthetic DNA primers shown by SEQ ID NO:12 and SEQ ID NO:13 and the synthetic DNA primers shown

35

by SEQ ID NO:14 and SEQ ID NO:15, respectively. The former DNA amplified was named human SLC-1(S) and the latter DNA amplified was named human SLC-1 (L). The synthetic DNA primers were constructed to amplify genes in the region to be translated into receptor proteins, whereby recognition sequences of the respective restriction enzymes were added at the 5' and 3' sides so that the base sequence recognized by restriction enzyme Sal I will be added at the 5' side of the gene and the base sequence recognized by restriction enzyme Spe I at the 3' side. The reaction solution for amplifying human SLC-1 (S) was composed of 5 µl of the plasmid template containing the human SLC-1 DNA sequence, 0.4 µM each of the synthetic DNA primers, 0.2 mM dNTPs, 0.5 µl of pfu DNA polymerase and a buffer attached to the enzyme, which were mixed together to make the total volume 50 µl. Using a Thermal Cycler (Perkin-Elmer Co.) for amplification, heating at 94°C for 60 seconds was followed by repeating 25 times a cycle set to include 94°C for 60 seconds, 57°C for 60 seconds and 72°C for 150 seconds, and finally maintaining at 72°C for 10 minutes. The reaction solution for amplifying human SLC-1 (L) was composed of 5 µl of the plasmid template containing the human SLC-1 DNA sequence, 0.4 µM each of the synthetic DNA primers, 0.2 mM dNTPs, 0.5 µl of pfu DNA polymerase and a buffer attached to the enzyme, which were mixed together to make the total volume 50 µl. Using a Thermal Cycler (Perkin-Elmer Co.) for amplification, heating at 94°C for 60 seconds was followed by repeating 25 times a cycle set to include 94°C for 60 seconds, 60°C for 60 seconds and 72°C for 3 minutes, and finally maintaining at 72°C for 10 minutes. The amplified products were confirmed by 0.8% agarose gel electrophoresis followed by staining with ethidium bromide.

EXAMPLE 11 Subcloning of the PCR products into plasmid vectors and confirmation of the amplified cDNA sequences by decoding base sequences of the inserted cDNA region

The PCR products obtained by PCR in EXAMPLE 10 were  
5 separated by using a 0.8% low melting point agarose gel. The band part was excised from the gel with a razor blade, cut into small pieces and extracted with phenol and then with phenol/chloroform. The extract was precipitated in ethanol to recover DNAs. According to the protocol attached  
10 to PCR-Script™ Amp SK(+) Cloning Kit (Stratagene Co.), the recovered DNAs were subcloned to plasmid vector pCR-Script Amp SK(+). The recombinant vector was introduced into *Escherichia coli* DH5α competent cells (Toyobo) to produce transformants. The clones having a cDNA-inserted fragment  
15 were selected in an LB agar medium containing ampicillin and X-gal. Only the clones exhibiting white color were picked up with a sterilized toothpick to obtain transformant *E. coli* DH5α/hSLC-1(S) of human SLC-1(S) and transformant *E. coli* DH5α/hSLC-1(L) of human SLC-1(L). The individual clones  
20 were cultured overnight in an LB medium containing ampicillin. Plasmid DNAs were prepared using QIA prep8 mini prep (Qiagen Co.). An aliquot of the DNAs thus prepared was cleaved by restriction enzymes Sal I and Spe I to confirm the size of the receptor cDNA fragment inserted. The reaction for base  
25 sequencing was carried out by using a DyeDeoxy Terminator Cycle Sequence Kit (Perkin-Elmer Co.), followed by decoding with a fluorescent automatic sequencer. The sequences of the clones obtained were in agreement, respectively, with the DNA sequence (SEQ ID NO:16) to be amplified by the  
30 synthetic DNA primers shown by SEQ ID NO:12 and SEQ ID NO:13 using the human SLC-1 gene as a template, and the DNA sequence (SEQ ID NO:17) to be amplified by the synthetic DNA primers shown by SEQ ID NO:14 and SEQ ID NO:15 using the human SLC-1 gene as a template.

EXAMPLE 12 Preparation of human SLC-1(S)-expression CHO cells and human SLC-1(L)-expression CHO cells

Using Plasmid Midi Kit (Qiagen Co.), plasmids were prepared from clones of *E. coli* transformed by the human SLC-1(S)- and human SLC-1(L)-introduced plasmids, whose sequences were confirmed in EXAMPLE 11. The plasmids were cleaved with restriction enzymes Sal I and Spe I to excise the insert part out. After electrophoresis, the inserted DNA was excised from the agarose gel with a razor blade, cut into small pieces and extracted with phenol and then with phenol/chloroform. The extract was precipitated in ethanol to recover the inserted DNA. The inserted DNA was added to Sal I- and Spe I-cleaved vector plasmid pAKK0-111H for animal cell expression (same as the vector plasmid pAKK01.11H described in Hinuma, S. et al., Biochim. Biophys. Acta, Vol. 1219, pp. 251-259 (1994)) followed by ligation using T4 ligase (Takara Shuzo Co.). Thus, plasmids pAKK0-hSLC-1(S) and pAKK0-hSLC-1(L) for protein expression were constructed.

After *E. coli* DH5 $\alpha$  (Toyobo) transformed by pAKK0-hSLC-1(S) and pAKK0-hSLC-1(L) was cultured, plasmid DNAs of pAKK0-hSLC-1(S) and pAKK0-hSLC-1(L) were prepared using Plasmid Midi Kit (Qiagen Co.). Using CellPfect Transfection Kit (Amersham Pharmacia Biotech Co.), the plasmid DNAs were introduced into CHO dhfr<sup>-</sup> cells, according to the protocol attached to the Kit. DNA, 10  $\mu$ g, was co-precipitated with calcium phosphate in suspension. The suspension was added to a 10 cm Petri dish on which  $5 \times 10^5$  or  $1 \times 10^6$  CHO dhfr<sup>-</sup> cells had been inoculated before 24 hours. The cells were cultured for one day in MEM $\alpha$  medium containing 10% calf fetal serum. After passage, the cells were cultured in nucleic acid-free MEM $\alpha$  medium for selection containing 10% dialyzed calf fetal serum. As clones growing in the selection medium, 56 clones of the transformant human SLC-1(S)-transfected CHO cells and 61 clones of the

transformant human SLC-1(L)-transfected CHO cells were selected.

5 EXAMPLE 13 Selection of transfectant cell line with high expression of human SLC-1(S) and human SLC-1(L) mRNAs

The expression amounts of the mRNAs of 56 clones from the CHO/hSLC-1(S) strain and 61 clones from the CHO/hSLC-1(L) strain established in EXAMPLE 12, were measured as follows, using a Cytostar T Plate (Amersham Pharmacia Biotech Co.),  
10 in accordance with the protocol attached. Each clone of the CHO/hSLC-1(S) strain and CHO/hSLC-1(L) strain was inoculated on each well of the Cytostar T Plate in  $2.5 \times 10^4$  cells/well. After culturing for 24 hours, the cells were fixed with 10% formalin. After 0.25% Triton X-100 was added  
15 to each well to increase the cell permeability,  $^{35}\text{S}$ -labeled riboprobe of SEQ ID NO:18 was added to the cells to hybridize them. By adding 20 mg/ml RNaseA to each well, free riboprobe was digested. After the plate was thoroughly washed, radioactivity of the hybridized riboprobe was measured with  
20 a Topcounter. The strain with a high radioactivity provides a high expression amount of mRNA.

EXAMPLE 14 cAMP synthesis inhibitory activity of MCH on human SLC-1-expression CHO cells

25 The synthetic MCH (Peninsula Co.) was diluted in various concentrations and the cAMP synthesis inhibitory activity was assayed on the human SLC-1-expression CHO cells by the following method. The CHO/hSLC-1(S) strain or the CHO/hSLC-1(L) strain, which was human SLC-1-expression CHO  
30 cells selected in EXAMPLE 13, was inoculated on a 24-well plate in  $5 \times 10^4$  cells/well followed by cultivation for 48 hours. The cells were then washed with Hanks' balanced salt solution (pH 7.4) containing 0.2 mM  
3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES  
35 (hereinafter Hanks' balanced salt solution (pH 7.4))

containing 0.2 mM 3-isobutylmethylxanthine, 0.05% BSA and 20 mM HEPES is referred to as a reaction buffer). Subsequently, 0.5 ml of the reaction buffer was added to the cells, which was maintained in the medium for 30 minutes. The reaction  
5 buffer was removed and 0.25 ml of a fresh reaction buffer was added to the cells. Then, 0.25 ml of the reaction buffer containing various amounts of MCH and 2  $\mu$ M forskolin was added to the cells followed by reacting at 37°C for 24 minutes. By adding 100  $\mu$ l of 20% perchloric acid, the reaction was  
10 terminated. Next, the reaction mixture was allowed to stand on ice for an hour to extract intracellular cAMP. The amount of cAMP in the extract was measured using cAMP EIA kit (Amersham Pharmacia Biotech). The results reveal that the MCH decreased dose-dependently the amount of intracellular  
15 cAMP in the human SLC-1 expression cells.

EXAMPLE 15 Arachidonic acid metabolite release activity induced by MCH on human SLC-1-expression CHO cells

The arachidonic acid metabolite release activity of  
20 the synthetic MCH (Peninsula Co.) in various concentrations on human SLC-1-expression CHO cells was assayed by the following method. The CHO/hSLC-1(S) strain or the CHO/hSLC-1(L) strain, which was human SLC-1-expression CHO cells selected in EXAMPLE 13, were inoculated on a 24-well  
25 plate in  $5 \times 10^4$  cells/well. After incubation for 24 hours, [ $^3$ H] arachidonic acid was added in 0.25  $\mu$ Ci/well. Sixteen hours after the addition of [ $^3$ H] arachidonic acid, the cells were washed with Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES. Then, 500  $\mu$ l of solutions  
30 in various concentrations of the synthetic MCH dissolved in Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES was added to each well. Hereinafter, Hanks' balanced salt solution (pH 7.4) containing 0.05% BSA and 20 mM HEPES is referred to as a reaction buffer. After  
35 incubating at 37°C for 60 minutes, 400  $\mu$ l of the reaction

solution was charged in a scintillator and the amount of [<sup>3</sup>H] arachidonic acid metabolites released into the reaction solution was measured using a scintillation counter. The results reveal that the synthetic MCH showed the arachidonic acid metabolite release activity dose-dependently on the human SLC-1 expression cells.

EXAMPLE 16 Assay for GTPγS binding activity using a human SLC-1-expression CHO cell membrane fraction

A human SLC-1-expression CHO cell membrane fraction was prepared by the following procedure. Human SLC-1-expression CHO cells ( $1 \times 10^8$  cells) were suspended in phosphate buffered saline (pH 7.4) supplemented with 5 mM EDTA (ethylenediaminetetraacetic acid) followed by centrifugation. After 10 ml of a homogenate buffer (10 mM NaHCO<sub>3</sub>, 5 mM EDTA, pH 7.5) was added to the cell pellets, the mixture was homogenized with a polytron homogenizer. The homogenate was then centrifuged at 400 x g for 15 minutes. The resulting supernatant was further centrifuged at 100,000 x g for an hour to give membrane fraction precipitates. The precipitates were suspended in 2 ml of an assay buffer [50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.1% BSA (bovine serum albumin), 10 mM MgCl<sub>2</sub>, 100 mM NaCl, 1 mM GDP (guanosine 5'-diphosphate), 0.25 mM PMSF (phenylmethylsulfonyl fluoride), 1 μg/ml pepstatin, 20 μg/ml leupeptin, 10 μg/ml phosphoramidon] and the suspension was centrifuged at 100,000 x g for an hour. The cell membrane recovered as precipitates was resuspended in 20 ml of the assay buffer. After dispensing, the suspension was stored at -80°C, which may be thawed every time at use.

The GTPγS binding activity was assayed as follows. The human SLC-1-expression CHO cell membrane fraction was diluted with the assay buffer. After dispensing 173 μl each of the dilution in a polypropylene-made 96-well plate, 2 μl of a DMSO solution of MCH (manufactured by Bachem Co.)



in various concentrations and 25  $\mu$ l of [ $^{35}$ S]-guanosine 5'-( $\gamma$ -thio)triphosphate (manufactured by Daiichi Kagaku Yakuhin K.K.) were added to each well at the same time (final concentration of the cell membrane: 20  $\mu$ g/ml, final  
5 concentration of [ $^{35}$ S]-guanosine 5'-( $\gamma$ -thio)triphosphate: 0.33 nM). After reacting at 25°C for an hour while stirring, the reaction solution was subjected to suction filtration through a glass filter (GF-C). The filtrate was further washed 3 times with 300  $\mu$ l of washing liquid (50 mM Tris-HCl  
10 buffer, pH 7.5). After adding 50  $\mu$ l of a liquid scintillator to the glass filter, the residual radioactivity was measured using a liquid scintillation counter.

The MCH increased dose-dependently the amount of [ $^{35}$ S]-guanosine 5'-( $\gamma$ -thio)triphosphate bound to the human  
15 SLC-1-expression CHO cell membrane fraction. Also, ED<sub>50</sub> value of the MCH to the human SLC-1-expression CHO cell membrane fraction was 0.2 nM.

EXAMPLE 17 Preparation of MCH(2-19), MCH(3-19), MCH(4-19),  
20 MCH(5-19), MCH(6-19) and MCH(7-19) (SEQ ID NO:19 - NO:24) by manually operated Edman degradation

In 30  $\mu$ l of 50% pyridine 0.1 mg of MCH (Sigma Co.) was dissolved and 1  $\mu$ l of phenyl isothiocyanate (Wako Pure Chemical Industries) was added to the solution for nitrogen  
25 substitution. The mixture was then kept at 45°C and stirring was made every 10 minutes. An hour later, the mixture was ceased to keep warm and evaporated to dryness in a nitrogen flow. The residue was again dissolved in 20  $\mu$ l of ethanol. The solution was evaporated to dryness by distilling the  
30 solvent off in vacuum. The reaction product or phenylthiocarbamoyl derivative was dissolved in 20  $\mu$ l of trifluoroacetic acid (Wako Pure Chemical Industries) followed by nitrogen substitution. By keeping warm at 45°C for 20 minutes, the amino terminal amino acid of the peptide  
35 was cleaved into the anilinothiazolinone derivative. After

removing trifluoroacetic acid in a nitrogen flow, 30  $\mu$ l of water and 100  $\mu$ l of n-butyl acetate were added to the solution. The mixture was extracted with n-butyl acetate to remove an excess of reagents and the anilinothiazolinone derivative. The extraction with n-butyl acetate was repeated 3 times. Subsequently, the aqueous phase containing MCH(2-19) with the amino terminus shortened by one residue was evaporated to dryness in vacuum in a nitrogen flow.

This degradation process was performed only once so that MCH(2-19) with only one residue deleted at the N terminus was obtained. The same degradation process was repeated 2, 3, 4, 5 or 6 times to give MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) with only one residue each of the N-terminal amino groups being deleted, respectively.

MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) obtained by the degradation described above were purified as follows and, their structures were confirmed by mass spectrometry and amino acid analysis. Though the details are focused on MCH(4-19) below, other derivatives were treated in almost the same way. The thus obtained analytical data on MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) are shown in TABLE 1.

TABLE 1. Data on MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) by mass spectrometry and amino acid analysis

Structure	Mass spectrum ( $M+H^+$ ) found (calcd.) Formula	Amino acid analysis (No. of residues)
MCH(2-19)	(2272.1) $C_{101}H_{156}N_{29}O_{23}S_4$	D 1.90 (1), E 2.28 (1), P 1.32 (1), G 2.33 (1), V 1.76 (2), C n. d. (1), M 0.46 (2), L 2.0 (2), Y 0.50 (1), F 0.93

		(1), R 1.98 (3)
MCH(3-19)	(2125.0) $C_{92}H_{147}N_{28}O_{22}S_4$	D 1.01 (1), E 1.05 (1), P 1.25 (1), G 1.02 (1), V 1.9 (2), C 0.30 (1), M 1.37 (2), L 2.0 (2), Y 0.20 (1), R 2.94 (3)
MCH(4-19)	(2010.0) $C_{88}H_{142}N_{27}O_{19}S_4$	E 1.04 (1), P 1.12 (1), G 1.02 (1), V 1.88 (2), C 0.34 (1), M 1.42 (2), L 2.0 (2), Y 0.23 (1), R 2.93 (3)
MCH(5-19)	(1878.9) $C_{83}H_{133}N_{26}O_{18}S_3$	E 1.51 (1), P 0.69 (1), G 2.16 (1), V 1.27 (2), C n. d. (1), M 0.38 (1), L 2.0 (2), Y 0.18 (1), R 1.80 (3)
MCH(6-19)	(1765.9) $C_{77}H_{122}N_{25}O_{17}S_3$	E 0.69 (1), P 0.79 (1), G 0.70 (1), V 1.21 (2), C 0.15 (1), M 0.50 (1), L 1.0 (1), Y 0.20 (1), R 1.84 (3)
MCH(7-19)	1609.2 (1608.8) $C_{71}H_{110}N_{21}O_{16}S_3$	E 0.90 (1), P 0.62 (1), G 1.03 (1), V 1.05 (2), C 0.07 (1), M 0.33 (1), L 1.0 (1), Y 0.15 (1), R 1.04 (2)

Using HPLC, MCH(4-19) was purified as follows. Eluant A (0.1% trifluoroacetic acid) was previously passed through a Spheri-5 RP-18 column for reverse phase high performance liquid chromatography (Brown-Lee Inc., 2.1 mm x 30 mm) at a flow rate of 300  $\mu$ l/min, to equilibrate the column at 25°C. The reaction product was dissolved in 270  $\mu$ l of 0.1% trifluoroacetic acid. After pouring a 50  $\mu$ l aliquot onto the column, the concentration of eluant B (0.1% trifluoroacetic acid/70% acetonitrile) was increased to 70% over 30 minutes while maintaining the flow rate at 300  $\mu$ l/min. The eluate was monitored at 210 nm in absorbance and the

peaks were manually fractionated. MCH(4-19) was eluted in 17.1 minutes. MCH(4-19) collected in one test tube was concentrated to dryness and the residue was dissolved in 100  $\mu$ l of DMSO.

5        Mass spectrometry was performed by the LSIMS method using JEOL JMS-HX110. That is, 1  $\mu$ l of a matrix of 3-nitrobenzyl alcohol and glycerol in 3:2 was mixed with 1  $\mu$ l of a sample fluid on a probe chip. The mixture was introduced into an ion source. Cesium ions accelerated to  
10    15 kV were irradiated and positive secondary ions formed were accelerated to 10 kV, which was led to a detector.

For amino acid analysis, hydrolysis was carried out by taking 5  $\mu$ l of a sample fluid in a glass tube, drying to solid in vacuum, putting the residue in a vial, charging  
15    200  $\mu$ l of 6N azeotropic hydrochloric acid (Pierce Co., Sequenal Grade) at the bottom of the vial, deaerating in accordance with the protocol recommended by Waters, Co. using Pico-Tag Work Station by Waters, Co., and then maintaining at 110°C for 24 hours.

20        The hydrochloric acid in the reaction vial was removed in vacuum through a vacuum pump, and the sample fluid was diluted with 150  $\mu$ l of 20 mM hydrochloric acid. The dilution was charged in a vial for analysis, which was set in an amino acid analyzer and a 100  $\mu$ l aliquot was provided for the  
25    analysis. Using a Hitachi L-8500 high speed amino acid analyzer, the amino acid analysis was performed by fluorometry using ortho-phthalaldehyde reagent (Wako Pure Chemical Industries) for derivatization. Preparation of a buffer for fluorometry, preparation of the reaction solution  
30    and conditions for analysis were followed in the manual of the L-8500 amino acid analyzer. A molar ratio of the measurement data based on leucine is given in TABLE 1.

Also, MCH or MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) can also be prepared by the solid phase synthesis  
35    described in EXAMPLES 24 through 28.

EXAMPLE 18 Derivatization of MCH, MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) with a non-isotope Bolton-Hunter reagent

5 MCH and, MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19) and MCH(6-19) obtained in EXAMPLE 17 were derivatized with a non-isotope Bolton-Hunter reagent. Taking derivatization of MCH(4-19) as an example, its procedure is described below.

After 1 nmol of MCH(4-19) was dissolved in 50  $\mu$ l of  
10 dimethylformamide, 100 nmols of N-succinimidyl 3-(4-hydroxy-3-iodophenyl)propionate (Wako Pure Chemical Industries) as a non-isotope Bolton-Hunter reagent and 100 nmols of N, N-diisopropylethylamine (Wako Pure Chemical Industries) were added to the solution. The mixture was  
15 reacted at 37°C for 4 hours.

After 450  $\mu$ l of 10% acetonitrile containing 0.1% trifluoroacetic acid was added to the reaction mixture, the mixture was purified by HPLC. Conditions for the chromatography are given below. Wakosil-II 5C18HG (4.6 x  
20 150 mm) was used as a column at a flow rate of 1.0 ml/min. Using aqueous acetonitrile solution containing 0.1% trifluoroacetic acid, elution was performed by maintaining the acetonitrile concentration at 10% for 2 minutes, then increasing up to 20% over 5 minutes and then increasing up  
25 to 50% over 20 minutes.

[N-(3-(4-Hydroxy-3-iodophenyl)propionyl)-Met<sup>4</sup>]-MCH(4-19)  
) derivatized from MCH(4-19) with the non-isotope Bolton-Hunter reagent was eluted in 22.9 minutes, which was manually fractionated. MCH or MCH(2-19), MCH(3-19),  
30 MCH(5-19) and MCH(6-19) were derivatized in substantially the same way by introducing 3-(4-hydroxy-3-iodophenyl)propionyl group at the amino group of the N-terminal amino acid. The derivatives were fractionated by HPLC. Acidic hydrolysis of these derivatives  
35 in a manner similar to the procedure described in EXAMPLE

17 was followed by amino acid analysis. The results are shown in TABLE 2.

TABLE 2. Amino acid analysis data on derivatized MCH(2-19),  
5 MCH(3-19), MCH(4-19), MCH(5-19) and MCH(6-19)

Structure	Amino Acid Analysis Data (No. of residues)
Derivatized MCH(2-19)	D 1.01 (1), E 1.05 (1), P 0.86 (1), G 1.09 (1), V 1.69 (2), C n. d. (1), M 1.01 (2), L 2.0 (2), Y 0.27 (1), F 0.90 (1), R 2.59 (3)
Derivatized MCH(3-19)	D 1.20 (1), E 1.58 (1), P 1.12 (1), G 2.07 (1), V 1.60 (2), C n. d. (1), M 0.94 (2), L 2.0 (2), Y 0.19 (1), R 2.24 (3)
Derivatized MCH(4-19)	E 1.09 (1), P 1.46 (1), G 1.09 (1), V 1.83 (2), C n. d. (1), M 1.14 (2), L 2.0 (2), Y 0.27 (1), R 2.78 (3)
Derivatized MCH(5-19)	E 1.10 (1), P 0.90 (1), G 1.34 (1), V 1.55 (2), C n. d. (1), M 0.32 (1), L 2.0 (2), Y 0.32 (1), R 2.28 (3)

#### EXAMPLE 19 Preparation of radioisotope-labeled MCH(4-19)

10 MCH(4-19) prepared in EXAMPLE 17, in which 3 residues of the N-terminal amino acid were deleted from MCH, was labeled with a radioisotope according to the Bolton-Hunter method. In a tube, dry nitrogen gas was blown into a solution of 9.25 MBq (0.11 nmol) of [<sup>125</sup>I]-Bolton-Hunter reagent  
15 (N-succinimidyl 3-(4-hydroxy-3-iodophenyl)propionate) (NEN Life Science Products Co., 81.4 TBq/mmol) in benzene to remove the benzene by distillation. In the tube were added 18 µl of 50 mM phosphate buffer (pH 7.5), 2.3 nmols of MCH(4-19) dissolved in 1.5 µl of dimethylsulfoxide and 0.5 µl of  
20 dimethylsulfoxide. The mixture was thoroughly mixed. After keeping the liquid mixture at 37°C for 2 hours, [<sup>125</sup>I]-[N-(3-(4-hydroxy-3-iodophenyl)propionyl)-Met<sup>4</sup>]-MCH(4-19) (structural formula is described in (4) supra), which is a radioactive derivative of MCH(4-19) with the a  
25 Bolton-Hunter reagent, was fractionated by reverse phase

HPLC.

[<sup>125</sup>I] - [N- (3- (4-Hydroxy-3-iodophenyl)propionyl) -Met<sup>4</sup>] -MCH(4-19) was eluted at about 43.6% acetonitrile concentration through an ODS column (TOSO, ODS-80TM (4.6 mm x 150 mm)).

5 In a similar manner, radioisotope-labeled derivatives of MCH, MCH(2-19), MCH(3-19), MCH(5-19), MCH(6-19) and MCH(7-19) ((1) through (3) and (5) through (7) *supra*) can be prepared by introducing  
[<sup>125</sup>I] - (3- (4-hydroxy-3-iodophenyl)propionyl group into the  
10 amino group of the N-terminal amino acid, using [<sup>125</sup>I] - Bolton-Hunter reagent.

EXAMPLE 20 Preparation of radioactive iodine-labeled MCH, MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and  
15 MCH(7-19)

Isotope-labeled MCH, MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) may also be prepared as follows, by converting Tyr<sup>13</sup> in the amino acid sequence into radioactive iodine. Taking MCH(4-19) as an example, its  
20 procedure will be described below but radioactive iodine derivatives of MCH, MCH(2-19), MCH(3-19), MCH(5-19), MCH(6-19) and MCH(7-19) can be prepared as in MCH(4-19).

In 25 µl of 0.4 M sodium acetate (pH 5.6) was dissolved 5 µg of MCH(4-19). After 200 ng of lacto-peroxidase  
25 (manufactured by Wako Pure Chemical Industries) was added to the solution, 1 mCi of [<sup>125</sup>I] -sodium iodide (Amersham Pharmacia Biotech Co.) and 200 ng of hydrogen peroxide (10 µl) were added to the mixture. After allowing to stand for 10 minutes at room temperature, 200 ng of hydrogen peroxide  
30 (10 µl) was further added to the mixture. The resulting mixture was then allowed to stand for 10 minutes. The mixture was purified by HPLC using a TSKgel ODS-80Ts column (4.6 mm x 25 cm, TOSO) gave [<sup>125</sup>I] -labeled MCH(4-19).

35 EXAMPLE 21 Assay for the agonist activity of MCH, MCH(2-19),

MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) using the GTP $\gamma$ S binding assay

A rat SLC-1-expression CHO cell membrane fraction was prepared by the following procedure. Rat SLC-1-expression CHO cells ( $1 \times 10^8$  cells) were suspended in phosphate buffered saline (pH 7.4) supplemented with 5 mM EDTA (ethylenediaminetetraacetic acid) followed by centrifugation. After 10 ml of a homogenate buffer (10 mM NaHCO<sub>3</sub>, 5 mM EDTA, pH 7.5) was added to the cell pellets, the mixture was homogenized with a polytron homogenizer. The homogenate was then centrifuged at 400 x g for 15 minutes. The resulting supernatant was further centrifuged at 100,000 x g for an hour to give membrane fraction precipitates. The precipitates were suspended in 2 ml of an assay buffer (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.1% BSA (bovine serum albumin), 10 mM MgCl<sub>2</sub>, 100 mM NaCl, 1  $\mu$ M GDP (guanosine 5'-diphosphate), 0.25 mM PMSF (phenylmethylsulfonyl fluoride), 1  $\mu$ g/ml pepstatin, 20  $\mu$ g/ml leupeptin, 10  $\mu$ g/ml phosphoramidon). The suspension was centrifuged at 100,000 x g for an hour. The cell membrane recovered as precipitates was resuspended in 20 ml of the assay buffer. After dispensing, the suspension was stored at -80°C, which may be thawed every time upon use.

The agonist activity of MCH, MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) was assayed as follows. The rat SLC-1-expression CHO cell membrane fraction was diluted with the assay buffer. After dispensing 173  $\mu$ l each of the dilution in a polypropylene-made 96-well plate, 2  $\mu$ l of solutions of MCH, MCH(2-19), MCH(3-19), MCH(4-19), MCH(5-19), MCH(6-19) and MCH(7-19) diluted with DMSO solution in various concentrations and 25  $\mu$ l of [<sup>35</sup>S]-guanosine 5'-( $\gamma$ -thio)triphosphate (manufactured by Daiichi Kagaku Yakuhin K.K.) were charged in each well at the same time (the final concentration of cell membrane: 20  $\mu$ g/ml, the final concentration of [<sup>35</sup>S]-guanosine



5'-( $\gamma$ -thio)triphosphate: 0.33 nM). The reaction solution was reacted at 25°C for an hour while stirring. The mixture was then subjected to suction filtration through a glass filter (GF-C). The filtrate was further washed 3 times with 300  $\mu$ l of washing liquid (50 mM Tris-HCl buffer, pH 7.5). After adding 50  $\mu$ l of a liquid scintillator to the glass filter, the residual radioactivity was measured using a liquid scintillation counter.

The agonist activity of MCH(6-19) and MCH(7-19) decreased by approximately 10 times and 200 times, respectively, as compared to that of MCH, whereas MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) showed almost the same agonist activity (FIG. 7).

EXAMPLE 22 Assay for the agonist activity of MCH, MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) derivatized with a non-isotope Bolton-Hunter reagent, using the GTP $\gamma$ S binding assay

The agonist activity of the non-isotope Bolton-Hunter reagent-derivatized MCH, MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) obtained in EXAMPLE 18 was assayed using the GTP $\gamma$ S binding assay in the same way as in EXAMPLE 21.

The derivatized MCH, MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) increased dose-dependently the amount of [<sup>35</sup>S]-guanosine 5'-( $\gamma$ -thio)triphosphate bound to the human SLC-1-expression CHO cell membrane fraction, confirming that various MCHs derivatized with a non-isotope Bolton-Hunter reagent exhibit the agonist activity (FIG. 8). In the figure, BH-MCH, BH-MCH(2-19), BH-MCH(3-19), BH-MCH(4-19) and BH-MCH(5-19) designate MCH, MCH(2-19), MCH(3-19), MCH(4-19) and MCH(5-19) derivatized with a non-isotope Bolton-Hunter reagent, respectively.

EXAMPLE 23 Receptor binding test using [<sup>125</sup>I]-labeled MCH(4-19) prepared using a Bolton-Hunter reagent

A receptor binding test was carried out using the [ $^{125}$ I]-labeled MCH(4-19) (whose structure is described in (4) supra) prepared in EXAMPLE 19 using a Bolton-Hunter reagent and the cell membrane fraction prepared from the human SLC-1-expression CHO cells.

The cell membrane fraction prepared from human SLC-1-expression CHO cells according to EXAMPLE 16 was diluted with an assay buffer (25 mM Tris-HCl, 1 mM EDTA (ethylenediaminetetraacetic acid), 0.1% BSA (bovine serum albumin), 0.25 mM PMSF (phenylmethylsulfonyl fluoride), 1  $\mu$ g/ml pepstatin, 20  $\mu$ g/ml leupeptin, 10  $\mu$ g/ml phosphoramidon, pH 7.5) in various concentration. Subsequently, 173  $\mu$ l each of the dilution was dispensed in a 96-well plate. To assay for the total binding (TB), 2  $\mu$ l of DMSO and 25  $\mu$ l of 100 pM [ $^{125}$ I]-labeled MCH(4-19) were added and to assay for non-specific binding (NSB), 2  $\mu$ l of a solution of 100  $\mu$ M MCH in DMSO and 25  $\mu$ l of 100 pM [ $^{125}$ I]-labeled MCH(4-19) were added, respectively, to the membrane fraction solution. After reacting at 25°C for 60 minutes, the reaction solution was suction-filtrated through a polyethyleneimine-treated Whatman glass filter (GF-C). After filtration, the residual radioactivity of [ $^{125}$ I]-labeled MCH(4-19) remained on the filter paper was measured with a  $\gamma$ -counter. As shown in FIG. 9, specific binding (SB) of [ $^{125}$ I]-labeled MCH(4-19) was recognized dependent on the concentration of the membrane fraction.

Also, by setting the membrane fraction concentration at 2.5  $\mu$ g/ml, 50% inhibitory concentration (IC<sub>50</sub> value) of MCH was calculated from the inhibition rate (%). The IC<sub>50</sub> value was found to be 0.2 nM (FIG. 10).

A similar binding test can be carried out using a membrane fraction prepared from the rat SLC-1-expression CHO cells and [ $^{125}$ I]-labeled MCH(4-19).

#### EXAMPLE 24 Preparation of MCH

(Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val)

In a reaction tank of peptide synthesizer ABI 430A, 0.5 mmol of commercially available Boc-Val-OCH<sub>2</sub>-PAM resin (0.77 mmol/g resin) was charged. In accordance with the Boc-strategy (NMP-HOBt) peptide synthesis, Boc-Gln, Boc-Trp(CHO), Boc-Cys(MeBzl), Boc-Pro, Boc-Arg(Tos), Boc-Tyr(Br-Z), Boc-Val, Boc-Arg(Tos), Boc-Gly, Boc-Leu, Boc-Met, Boc-Cys(MeBzl), Boc-Arg(Tos), Boc-Leu, Boc-Met, Boc-Asp(OcHex), Boc-Phe and Boc-Asp(OcHex) were introduced into the resin in this order to give the desired protected peptide resin. The resulting resin, 0.6 g, was stirred at 0°C for 60 minutes in 10 ml of anhydrous hydrogen fluoride together with 2 g of p-cresol and 1.2 ml of 1,4-butanedithiol. The hydrogen fluoride was then distilled off in vacuum. Diethyl ether was added to the residue and the precipitate was filtrated. Aqueous 50% acetic acid solution was added to the precipitate for extraction and insoluble matters were removed. After the extract was sufficiently concentrated, the concentrate was applied to Sephadex (trade name) G-25 column (2.0 x 80 cm) filled with 50% acetic acid aqueous solution followed by development with the same solvent. The main fractions were collected and applied to reverse phase chromatography column (2.6 x 60 cm) packed with LiChroprep (trade name) RP-18 followed by washing with 200 ml of water containing 0.1% TFA. Linear density gradient elution was performed with 300 ml of water containing 0.1% TFA and 300 ml of 40% aqueous acetonitrile solution containing 0.1% TFA. The main fractions were collected and concentrated. The concentrate was dissolved in approximately 4 ml of acetic acid. After diluting the solution with distilled water to a volume of 240 ml, pH was adjusted to 7.5 with ammonia water. The dilution was stirred while mildly blowing air therein. The reaction was traced by HPLC. After it was confirmed that the peaks of the SH form peptide were all converted into

the SS form, acetic acid was added to adjust pH of the solution to 3. Then the solution was adsorbed onto the LiChroprep (trade name) RP-18 column *supra*. After washing the column with 200 ml of water containing 0.1% TFA, linear density  
5 gradient elution was carried out using 300 ml of water containing 0.1% TFA and 300 ml of 50% acetonitrile aqueous solution containing 0.1% TFA. The main fractions were collected and lyophilized to give the desired peptide. Mass spectrum (M+H)<sup>+</sup> 2387.3 (calcd. 2387.9)

10 Elution time on HPLC: 20.9 mins.

Column conditions:

Column: Wakosil-II 5C18HG (4.6 x 150 mm)

Eluant: linear density gradient elution with eluants  
A/B = 20/80 - 80/20, using 10% acetonitrile aqueous  
15 solution containing 0.1% TFA as eluant A and 60% acetonitrile aqueous solution containing 0.1% TFA (20 mins.)

Flow rate: 1.0 ml/min.

20 EXAMPLE 25 Preparation of Des-Asp<sup>1</sup>-MCH (MCH(2-19), Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln-Val)

In a reaction tank of peptide synthesizer ABI 430A, 0.5 mmol of commercially available Boc-Val-OCH<sub>2</sub>-PAM resin  
25 (0.77 mmol/g resin) was charged. According to the Boc-strategy (NMP-HOBt) peptide synthesis, Boc-Gln, Boc-Trp(CHO), Boc-Cys(MeBzl), Boc-Pro, Boc-Arg(Tos), Boc-Tyr(Br-Z), Boc-Val, Boc-Arg(Tos), Boc-Gly, Boc-Leu, Boc-Met, Boc-Cys(MeBzl), Boc-Arg(Tos), Boc-Leu, Boc-Met,  
30 Boc-Asp(OcHex) and Boc-Phe were introduced into the resin in this order to give the desired protected peptide resin. The resulting resin was treated as in EXAMPLE 25 by removal of the protecting groups, cyclization and purification to give the desired peptide.

35 Mass spectrum (M+H)<sup>+</sup> 2272.3 (calcd. 2272.1)

Elution time on HPLC: 20.6 mins.

Column conditions:

Column: Wakosil-II 5C18HG (4.6 x 150 mm)

Eluant: linear density gradient elution with eluants  
A/B = 20/80 - 80/20, using 10% acetonitrile aqueous  
solution containing 0.1% TFA as eluant A and 60%  
acetonitrile aqueous solution containing 0.1% TFA  
(20 mins.)

Flow rate: 1.0 ml/min.

EXAMPLE 26 Preparation of Des- [Asp<sup>1</sup>, Phe<sup>2</sup>] -MCH (MCH(3-19),  
Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys  
-Trp-Gln-Val)

In a reaction tank of peptide synthesizer ABI 430A,  
0.5 mmol of commercially available Boc-Val-OCH<sub>2</sub>-PAM resin  
(0.77 mmol/g resin) was charged. According to the  
Boc-strategy (NMP-HOBt) peptide synthesis, Boc-Gln,  
Boc-Trp(CHO), Boc-Cys(MeBzl), Boc-Pro, Boc-Arg(Tos),  
Boc-Tyr(Br-Z), Boc-Val, Boc-Arg(Tos), Boc-Gly, Boc-Leu,  
Boc-Met, Boc-Cys(MeBzl), Boc-Arg(Tos), Boc-Leu, Boc-Met  
and Boc-Asp(OcHex) were introduced into the resin in this  
order to give the desired protected peptide resin. The  
resulting resin was treated as in EXAMPLE 24 by removal of  
the protecting groups, cyclization and purification to give  
the desired peptide.

Mass spectrum (M+H)<sup>+</sup> 2124.8 (calcd. 2125.0)

Elution time on HPLC: 19.2 mins.

Column conditions:

Column: Wakosil-II 5C18HG (4.6 x 150 mm)

Eluant: linear density gradient elution with eluants  
A/B = 20/80 - 80/20, using 10% acetonitrile aqueous  
solution containing 0.1% TFA as eluant A and 60%  
acetonitrile aqueous solution containing 0.1% TFA  
(20 mins.)

Flow rate: 1.0 ml/min.

EXAMPLE 27 Preparation of Des-[Asp<sup>1</sup>,Phe<sup>2</sup>,Asp<sup>3</sup>]-MCH  
(MCH(4-19),

Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp  
5 -Gln-Val)

In a reaction tank of peptide synthesizer ABI 430A,  
0.5 mmol of commercially available Boc-Val-OCH<sub>2</sub>-PAM resin  
(0.77 mmol/g resin) was charged. According to the  
Boc-strategy (NMP-HOBt) peptide synthesis, Boc-Gln,  
10 Boc-Trp(CHO), Boc-Cys(MeBzl), Boc-Pro, Boc-Arg(Tos),  
Boc-Tyr(Br-Z), Boc-Val, Boc-Arg(Tos), Boc-Gly, Boc-Leu,  
Boc-Met, Boc-Cys(MeBzl), Boc-Arg(Tos), Boc-Leu and Boc-Met  
were introduced into the resin in this order to give the  
desired protected peptide resin. The resulting resin was  
15 treated as in EXAMPLE 24 by removal of the protecting groups,  
cyclization and purification to give the desired peptide.  
Mass spectrum (M+H)<sup>+</sup> 2009.9 (calcd. 2010.0)  
Elution time on HPLC: 17.9 mins.

Column conditions:

20 Column: Wakosil-II 5C18HG (4.6 x 150 mm)

Eluant: linear density gradient elution with eluants  
A/B = 20/80 - 80/20, using 10% acetonitrile aqueous  
solution containing 0.1% TFA as eluant A and 60%  
acetonitrile aqueous solution containing 0.1% TFA  
25 (20 mins.)

Flow rate: 1.0 ml/min.

EXAMPLE 28 Preparation of Des-[Asp<sup>1</sup>,Phe<sup>2</sup>,Asp<sup>3</sup>,Met<sup>4</sup>]-MCH  
(MCH(5-19),

30 Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Tyr-Arg-Pro-Cys-Trp-Gln  
-Val-OH)

In a reaction tank of peptide synthesizer ABI 430A,  
0.5 mmol of commercially available Boc-Val-OCH<sub>2</sub>-PAM resin  
(0.77 mmol/g resin) was charged. According to the  
35 Boc-strategy (NMP-HOBt) peptide synthesis, Boc-Gln,

Boc-Trp(CHO), Boc-Cys(MeBzl), Boc-Pro, Boc-Arg(Tos),  
Boc-Tyr(Br-Z), Boc-Val, Boc-Arg(Tos), Boc-Gly, Boc-Leu,  
Boc-Met, Boc-Cys(MeBzl), Boc-Arg(Tos) and Boc-Leu were  
introduced into the resin in this order to give the desired  
5 protected peptide resin. The resulting resin was treated  
as in 24 by removal of the protecting groups, cyclization  
and purification to give the desired peptide.

Mass spectrum (M+H)<sup>+</sup> 1878.9 (calcd. 1878.9)

Elution time on HPLC: 17.4 mins.

10 Column conditions:

Column: Wakosil-II 5C18HG (4.6 x 150 mm)

Eluant: linear density gradient elution with eluants  
A/B = 20/80 - 80/20, using 10% acetonitrile aqueous  
solution containing 0.1% TFA as eluant A and 60%  
15 acetonitrile aqueous solution containing 0.1% TFA  
(20 mins.)

Flow rate: 1.0 ml/min.

(Sequence Listing Free Text)

20

SEQ ID NO: 1

Other information on the sequence: The two Cys residues  
at the 7th and 16th form intramolecular disulfide bond.

SEQ ID NO: 2

25

Other information on the sequence: The two Cys residues  
at the 7th and 16th form intramolecular disulfide bond.

SEQ ID NO: 19

Other information on the sequence: The two Cys residues  
at the 6th and 15th form intramolecular disulfide bond.

30

SEQ ID NO: 20

Other information on the sequence: The two Cys residues  
at the 5th and 14th form intramolecular disulfide bond.

SEQ ID NO: 21

35

Other information on the sequence: The two Cys residues  
at the 4th and 13th form intramolecular disulfide bond.

Other information on the sequence: The two Cys residues at the 3rd and 12th form intramolecular disulfide bond.

5      Other information on the sequence: The two Cys residues  
at the 2nd and 11th form intramolecular disulfide bond.

Other information on the sequence: The two Cys residues at the 1st and 10th form intramolecular disulfide bond.

10

The method for screening a compound or its salts that alter the binding property between MCH or its derivative or a salt thereof and the SLC-1 or its salt, characterized by using the MCH of the present invention or its derivative or a salt thereof and the SLC-1 or its salt is useful for screening SLC-1 agonists which can be used not only as appetite (eating) promoting agents but also as prophylactic/therapeutic agents for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, etc., and SLC-1 antagonists which can be used not only as antiobestic agents (drugs), appetite (eating) modulators, etc. but also as prophylactic/therapeutic agents for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Willi syndrome, etc.



## CLAIMS

1. A method for screening a compound or its salt that alters the binding property between a melanin concentrating hormone (MCH) or its salt and SLC-1 or its salt, which  
5 comprises using the MCH or its derivative, or a salt thereof and the SLC-1 or its salt.
2. A kit for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1  
10 or its salt, comprising the MCH or its derivative, or a salt thereof and the SLC-1 or its salt.
3. A compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, which is obtainable by using the screening method according to  
15 claim 1 or the screening kit according to claim 2.
4. A pharmaceutical composition comprising the compound or its salt according to claim 3.
5. A pharmaceutical composition according to claim 4, which is an antiobestic agent.
- 20 6. A protein containing the amino acid sequence represented by SEQ ID NO:11, or a salt thereof.
7. A DNA containing a DNA having a base sequence encoding the protein according to claim 6.
8. A screening method according to claim 1 or a  
25 screening kit according to claim 2, wherein the MCH is a peptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:2.
9. A screening method according to claim 1 or a  
30 screening kit according to claim 2, wherein the derivative is a peptide containing a sequence of the 5th to the 19th from the N terminus of the amino acid sequence represented by SEQ ID NO:2.
10. A screening method according to claim 1 or a  
35 screening kit according to claim 2, wherein the derivative

5           11. MCH derivatized with a Bolton-Hunter reagent, or  
a peptide or its salt derivatized with a Bolton-Hunter  
reagent and containing a sequence of the 5th to the 19th  
from the N terminus of the amino acid sequence represented  
by SEQ ID NO:2. .

15


## ABSTRACT OF THE DISCLOSURE

The present invention provides a method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt; and the like.

The method for screening a compound or its salt that alters the binding property between MCH or its salt and SLC-1 or its salt, characterized by using MCH or its derivative or a salt thereof and SLC-1 or its salt is useful for screening an SLC-1 agonist which can be used not only as an appetite (eating) promoting agent but also as a prophylactic/therapeutic agent for weak pains, atonic bleeding, before and after expulsion, subinvolution of uterus, cesarean section, induced abortion, galactostasis, etc., and an SLC-1 antagonist which can be used not only as an antiobestic agents (drug), an appetite (eating) modulator, etc. but also as a prophylactic/therapeutic agent for hyperstimulation, ankylosing uterine contractions, fetal distress, uterine rupture, cervical laceration, preterm delivery, Prader-Willi syndrome, etc.

1/10

Fig.1



2/10

Fig.2




Fig.3





Fig.4





Fig.5





6/10

Fig.6




Fig.7




Fig.8




Fig.9





Fig.10



DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP  
130 Water Street  
Boston, Massachusetts 02109

Page 1 of 4

### DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

which is described and claimed in:

- ☐ the specification attached hereto.
- ☐ the specification in U.S. Application Serial Number \_\_\_\_\_, filed on \_\_\_\_\_.

☒ the specification in PCT international application Number PCT/JP99/07337, filed on December 27, 1999, and was amended on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:			
Application No.	Filing Date	Country	Priority Claimed Under 35 U.S.C. §119?
374454/1998	December 28, 1998	JP	X
122688/1999	April 28, 1999	JP	X
249300/1999	September 2, 1999	JP	X
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S-Benefit Under 35 U.S.C. §120					
U.S. Applications		Status (Check One)			
Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned	
PCT Applications Designating the U.S.					
Application No.	Filing Date	U.S. Serial No. Assigned			

**CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)**  
(35 U.S.C. §119(e))

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Applicant	Provisional Application Number	Filing Date

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Sewall P. Bronstein (Reg. No. 16,919)	Peter F. Corless (Reg. No. 33,860)	Richard E. Gamache (Reg. No. 39,196)
David G. Conlin (Reg. No. 27,026)	Cara Z. Lowen (Reg. No. 38,227)	David A. Tucker (Reg. No. 27,840)
George W. Neuner (Reg. No. 26,964)	William J. Daley, Jr. (Reg. No. 35,487)	Lisa Hazzard Swiszc (Reg. No. 44,368)
Linda M. Buckley (Reg. No. 31,003)	Robert L. Buchanan (Reg. No. 40,927)	
Peter J. Manus (Reg. No. 26,766)	Christine C. O'Day (Reg. No. 38,256)	

**SEND CORRESPONDENCE TO:**

David G. Conlin  
Dike, Bronstein, Roberts & Cushman, LLP  
130 Water Street  
Boston, Massachusetts-02109

**DIRECT TELEPHONE CALLS TO:**

(617) 523-3400

1-00

2 0 1	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		
		<u>Mori</u>	<u>Masaaki</u>	
		<u>Ibaraki</u>	Japan <u>JPK</u>	Japan
	8-5, Kasuga 3-chome, Tsukuba-shi, Ibaraki 305-0821 Japan			

2-00

2 0 2	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		
		<u>Shimomura</u>	<u>Yukio</u>	
		<u>Ibaraki</u>	Japan <u>JPK</u>	Japan
	12-1-410, Matsushiro 3-chome, Tsukuba-shi, Ibaraki 305-0035 Japan			

3-00

2 0 3	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		
		<u>Takekawa</u>	<u>Shiro</u>	
		<u>Ibaraki</u>	Japan <u>JPK</u>	Japan
	5-3-B305, Umezono 2-chome, Tsukuba-shi, Ibaraki 305-0045 Japan			

4-00

2 0 4	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		
		<u>Sugo</u>	<u>Tsukasa</u>	
		<u>Ibaraki</u>	Japan <u>JPK</u>	Japan
	7-26-301, Hanabatake 2-chome, Tsukuba-shi, Ibaraki 300-3261 Japan			

5-00

2 0 5	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		
		<u>Ishibashi</u>	<u>Yoshihiro</u>	
		<u>Ibaraki</u>	Japan <u>JPK</u>	Japan
	25-1, Sakura 2-chome, Tsukuba-shi, Ibaraki 305-0003 Japan			



6-00

2 0 6	FULL NAME OF INVENTOR	LAST NAME <u>Kitada</u>	FIRST NAME <u>Chieko</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Osaka</u>	STATE OR FOREIGN COUNTRY Japan <u>JPK</u>	COUNTRY OF CITIZENSHIP Japan
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 2-8, Minamikoyochō 1-cho, Sakai-shi, Osaka 590-0073 Japan		

7-00

2 0 7	FULL NAME OF INVENTOR	LAST NAME <u>Suzuki</u>	FIRST NAME <u>Nobuhiro</u>	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Ibaraki</u>	STATE OR FOREIGN COUNTRY Japan <u>JPK</u>	COUNTRY OF CITIZENSHIP Japan
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 1077-50, Oaza-yatabe, Tsukuba-shi, Ibaraki 305-0861 Japan		

2 0 8	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		

2 0 9	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		

2 1 0	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS		

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 Masaaki Mori <i>Masaaki Mori</i>	Date: May 14, 2001
Signature of Inventor 202 Yukio Shimomura <i>Yukio Shimomura</i>	Date: May 15, 2001
Signature of Inventor 203 Shiro Takekawa <i>Shiro Takekawa</i>	Date: May 14, 2001
Signature of Inventor 204 Tsukasa Sugo <i>Tsukasa Sugo</i>	Date: May 14, 2001
Signature of Inventor 205 Yoshihiro Ishibashi <i>Yoshihiro Ishibashi</i>	Date: May 15, 2001
Signature of Inventor 206 Chieko Kitada <i>Chieko Kitada</i>	Date: May 15, 2001
Signature of Inventor 207 Nobuhiro Suzuki <i>Nobuhiro Suzuki</i>	Date: May 14, 2001
Signature of Inventor 208	Date:
Signature of Inventor 209	Date:
Signature of Inventor 210	Date:

## SEQUENCE LISTING

<110> Takeda Chemical Industries, Ltd.

<120> Screening Method

<130> 2601W00P

<150> JP 10-374454

<151> 1998-12-28

<150> JP 11-122688

<151> 1999-04-28

<150> JP 11-249300

<151> 1999-09-02

<160> 24

<210> 1

<211> 16

<212> PRT

<213> Rat

<223> The 7th cystein residue binds with the 16th cystein residue to form  
a intra-molecular disulfide-bond.

<400> 1

Asp Phe Asp Met Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys

1

5

10

15

<210> 2

<211> 19

<212> PRT

<213> Rat

<223> The 7th cystein residue binds with the 16th cystein residue to form  
a intra-molecular disulfide-bond.

<400> 2

2/15

Asp Phe Asp Met Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys

1 5 10 15

Trp Gln Val

19

<210> 3

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 3

GTCGACATGG ATCTGCAAAC CTCGTTGCTG TG 32

<210> 4

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223>

<400> 4

ACTAGTTCAG GTGCCTTTGC TTTCTGTCCT CT 32

<210> 5

<211> 353

<212> PRT

<213> Rat

<400> 5

Met Asp Leu Gln Thr Ser Leu Leu Ser Thr Gly Pro Asn Ala Ser Asn

1 5 10 15

3/15

Ile Ser Asp Gly Gln Asp Asn Leu Thr Leu Pro Gly Ser Pro Pro Arg  
 20 25 30  
 Thr Gly Ser Val Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe Gly  
 35 40 45  
 Thr Ile Cys Leu Leu Gly Ile Val Gly Asn Ser Thr Val Ile Phe Ala  
 50 55 60  
 Val Val Lys Lys Ser Lys Leu His Trp Cys Ser Asn Val Pro Asp Ile  
 65 70 75 80  
 Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Leu Gly Met  
 85 90 95  
 Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe Gly  
 100 105 110  
 Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe  
 115 120 125  
 Thr Ser Thr Tyr Ile Leu Thr Ala Met Thr Ile Asp Arg Tyr Leu Ala  
 130 135 140  
 Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Met Ala  
 145 150 155 160  
 Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr  
 165 170 175  
 Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala Val  
 180 185 190  
 Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp Phe  
 195 200 205  
 Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val Ile  
 210 215 220  
 Thr Ala Ala Tyr Val Lys Ile Leu Gln Arg Met Thr Ser Ser Val Ala

4/15

225                      230                      235                      240  
 Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr Lys Arg Val Thr Arg  
                          245                      250                      255  
 Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val Cys Trp Ala Pro Tyr  
                          260                      265                      270  
 Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser Arg Pro Thr Leu Thr  
                          275                      280                      285  
 Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu Gly Tyr Ala Asn Ser  
                          290                      295                      300  
 Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys Glu Thr Phe Arg Lys  
 305                      310                      315                      320  
 Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln Gly Gln Leu Arg Thr  
                          325                      330                      335  
 Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg Thr Glu Ser Lys Gly  
                          340                      345                      350

Thr

&lt;210&gt; 6

&lt;211&gt; 1074

&lt;212&gt; DNA

&lt;213&gt; Rat

&lt;400&gt; 6

GTCGACATGG ATCTGCAAAC CTCGTTGCTG TCCACTGGCC CCAATGCCAG CAACATCTCC 60  
 GATGGCCAGG ATAATCTCAC ATTGCCGGGG TCACCTCCTC GCACAGGGAG TGTCTCCTAC 120  
 ATCAACATCA TTATGCCTTC CGTGTTTGGT ACCATCTGTC TCCTGGGCAT CGTGGGAAAC 180  
 TCCACGGTCA TCTTTGCTGT GGTGAAGAAG TCCAAGCTAC ACTGGTGCAG CAACGTCCCC 240  
 GACATCTTCA TCATCAACCT CTCTGTGGTG GATCTGCTCT TCCTGCTGGG CATGCCTTTC 300  
 ATGATCCACC AGCTCATGGG GAACGGCGTC TGGCACTTTG GGGAAACCAT GTGCACCCTC 360

5/15

ATCACAGCCA TGGACGCCAA CAGTCAGTTC ACTAGCACCT ACATCCTGAC TGCCATGACC 420  
 ATTGACCGCT ACTTGGCCAC CGTCCACCCC ATCTCCTCCA CCAAGTTCCG GAAGCCCTCC 480  
 ATGGCCACCC TGGTGATCTG CCTCCTGTGG GCGCTCTCCT TCATCAGTAT CACCCCTGTG 540  
 TGGCTCTACG CCAGGCTCAT TCCCTTCCCA GGGGGTGTG TGGGCTGTGG CATCCGCCTG 600  
 CCAAACCCGG AACTGACCT CTACTGGTTC ACTCTGTACC AGTTTTTCCT GGCCTTTGCC 660  
 CTTCCGTTTG TGGTCATTAC CGCCGCATAC GTGAAAATAC TACAGCGCAT GACGTCTTCG 720  
 GTGGCCCCAG CCTCCCAACG CAGCATCCGG CTTCGGACAA AGAGGGTGAC CCGCACGGCC 780  
 ATTGCCATCT GTCTGGTCTT CTTTGTGTGC TGGGCACCCT ACTATGTGCT GCAGCTGACC 840  
 CAGCTGTCCA TCAGCCGCCC GACCCTCAG TTTGTCTACT TGTACAACGC GGCCATCAGC 900  
 TTGGGCTATG CTAACAGCTG CCTGAACCCC TTTGTGTACA TAGTGCTCTG TGAGACCTTT 960  
 CGAAAACGCT TGGTGTTGTC AGTGAAGCCT GCAGCCCAGG GGCAGTCCG CACGGTCAGC 1020  
 AACGCTCAGA CAGCTGATGA GGAGAGGACA GAAAGCAAAG GCACCTGAAC TAGT 1074

<210> 7

<211> 326

<212> RNA

<213> Rat

<400> 7

GCGAAUUGGG UACCGGGCCC CCCUCGAGG UCGACGGUUA CGAUAAGCUU GAUAUCGAAU 60  
 UCCUGCAGCC CGGGGGAUCC GCCCACUAGU UCAGGUGCCU UUGCUUUCUG UCCUCUCCUC 120  
 AUCAGCUGUC UGAGCGUUGC UGACCGUGCG GAGCUGCCCC UGGGCUGCAG GCUUCACUGA 180  
 CAACACCAAG CGUUUUCGAA AGGUCUCACA GAGCACUAUG UACACAAAGG GGUUCAGGCA 240  
 GCUGUUAGCA UAGCCCAAGC UG 262

<210> 8

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

6/15

&lt;223&gt;

&lt;400&gt; 8

CAACAGCTGC CTCAACCC 18

&lt;210&gt; 9

&lt;211&gt; 18

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt;

&lt;400&gt; 9

CCTGGTGATC TGCCTCCT 18

&lt;210&gt; 10

&lt;211&gt; 1275

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 10

TAGGTGATGT CAGTGGGAGC CATGAAGAAG GGAGTGGGGA GGGCAGTTGG GCTTGGAGGC 60  
GGCAGCGGCT GCCAGGCTAC GGAGGAAGAC CCCCTTCCCA ACTGCGGGGC TTGCGCTCCG 120  
GGACAAGGTG GCAGGCGCTG GAGGCTGCCG CAGCCTGCGT GGGTGGAGGG GAGCTCAGCT 180  
CGGTTGTGGG AGCAGGCGAC CGGCACTGGC TGGATGGACC TGAAGCCTC GCTGCTGCCC 240  
ACTGGTCCCA ACGCCAGCAA CACCTCTGAT GGCCCCGATA ACCTCACTTC GGCAGGATCA 300  
CCTCCTCGCA CGGGGAGCAT CTCCTACATC AACATCATCA TGCCTTCGGT GTTCGGCACC 360  
ATCTGCCTCC TGGGCATCAT CGGGAActCC ACGGTCATCT TCGCGGTCGT GAAGAAGTCC 420  
AAGCTGCACT GGTGCAACAA CGTCCCCGAC ATCTTCATCA TCAACCTCTC GGTAGTAGAT 480  
CTCCTCTTTC TCCTGGGCAT GCCCTTCATG ATCCACCAGC TCATGGGCAA TGGGGTGTGG 540  
CACTTTGGGG AGACCATGTG CACCCTCATC ACGGCCATGG ATGCCAATAG TCAGTTCACC 600  
AGCACCTACA TCCTGACCGC CATGGCCATT GACCGCTACC TGGCCACTGT CCACCCCATC 660



$\langle 210 \rangle$  11

&lt;212&gt; PRT

<400> 11

MeT Ser Val Gly Ala MeT Lys Lys Gly Val Gly Arg Ala Val Gly Leu  
1 5 10 15  
Gly Gly Gly Ser Gly Cys Gln Ala Thr Glu Glu Asp Pro Leu Pro Asn  
20 25 30  
Cys Gly Ala Cys Ala Pro Gly Gln Gly Gly Arg Arg Trp Arg Leu Pro  
35 40 45  
Gln Pro Ala Trp Val Glu Gly Ser Ser Ala Arg Leu Trp Glu Gln Ala  
50 55 60  
Thr Gly Thr Gly Trp MeT Asp Leu Glu Ala Ser Leu Leu Pro Thr Gly  
65 70 75 80  
Pro Asn Ala Ser Asn Thr Ser Asp Gly Pro Asp Asn Leu Thr Ser Ala

	85		90		95
Gly Ser Pro Pro Arg Thr Gly Ser Ile Ser Tyr Ile Asn Ile Ile Met					
	100		105		110
Pro Ser Val Phe Gly Thr Ile Cys Leu Leu Gly Ile Ile Gly Asn Ser					
	115		120		125
Thr Val Ile Phe Ala Val Val Lys Lys Ser Lys Leu His Trp Cys Asn					
	130		135		140
Asn Val Pro Asp Ile Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu					
145		150		155	160
Phe Leu Leu Gly MeT Pro Phe MeT Ile His Gln Leu MeT Gly Asn Gly					
	165		170		175
Val Trp His Phe Gly Glu Thr MeT Cys Thr Leu Ile Thr Ala MeT Asp					
	180		185		190
Ala Asn Ser Gln Phe Thr Ser Thr Tyr Ile Leu Thr Ala MeT Ala Ile					
	195		200		205
Asp Arg Tyr Leu Ala Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg					
	210		215		220
Lys Pro Ser Val Ala Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser					
225		230		235	240
Phe Ile Ser Ile Thr Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe					
	245		250		255
Pro Gly Gly Ala Val Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr					
	260		265		270
Asp Leu Tyr Trp Phe Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu					
	275		280		285
Pro Phe Val Val Ile Thr Ala Ala Tyr Val Arg Ile Leu Gln Arg MeT					
	290		295		300

9/15

Thr Ser Ser Val Ala Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr  
 305                      310                      315                      320  
 Lys Arg Val Thr Arg Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val  
                          325                      330                      335  
 Cys Trp Ala Pro Tyr Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser  
                          340                      345                      350  
 Arg Pro Thr Leu Thr Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu  
                          355                      360                      365  
 Gly Tyr Ala Asn Ser Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys  
                          370                      375                      380  
 Glu Thr Phe Arg Lys Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln  
 385                      390                      395                      400  
 Gly Gln Leu Arg Ala Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg  
                          405                      410                      415  
 Thr Glu Ser Lys Gly Thr  
                          420

&lt;210&gt; 12

&lt;211&gt; 31

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt;

&lt;400&gt; 12

GTCCACATGG ACCTGGAAGC CTCGCTGCTG C     31

&lt;210&gt; 13

&lt;211&gt; 31

&lt;212&gt; DNA

$\langle 220 \rangle$ 

<400> 13

&lt;210&gt; 14

## <212> DNA

 $\langle 220 \rangle$ 

<400> 14

&lt;210&gt; 15

&lt;211&gt; 33

## <212> DNA

 $\langle 220 \rangle$ 

〈223〉

<400> 15

&lt;210&gt; 16

&lt;211&gt; 1074

$\langle 212 \rangle$  DNA

〈213〉 Human

<400> 16

GTGACATGG ACCTGGAAGC CTCGCTGCTG CCCACTGGTC CCAACGCCAG CAACACCTCT 60

11/15

GATGGCCCCG ATAACCTCAC TTCGGCAGGA TCACCTCCTC GCACGGGGAG CATCTCCTAC 120  
 ATCAACATCA TCATGCCTTC GGTGTTCCGGC ACCATCTGCC TCCTGGGCAT CATCGGGAAC 180  
 TCCACGGTCA TCTTCGCGGT CGTGAAGAAG TCCAAGCTGC ACTGGTGCAA CAACGTCCCC 240  
 GACATCTTCA TCATCAACCT CTCGGTAGTA GATCTCCTCT TTCTCCTGGG CATGCCCTTC 300  
 ATGATCCACC AGCTCATGGG CAATGGGGTG TGGCACTTTG GGGAGACCAT GTGCACCCTC 360  
 ATCACGGCCA TGGATGCCAA TAGTCAGTTC ACCAGCACCT ACATCCTGAC CGCCATGGCC 420  
 ATTGACCGCT ACCTGGCCAC TGTCCACCCC ATCTCTTCCA CGAAGTCCG GAAGCCCTCT 480  
 GTGGCCACCC TGGTGATCTG CCTCCTGTGG GCCCTCTCCT TCATCAGCAT CACCCCTGTG 540  
 TGGCTGTATG CCAGACTCAT CCCCTTCCCA GGAGGTGCAG TGGGCTGCGG CACACGCTG 600  
 CCCAACCCAG ACACTGACCT CTA CTGTTTCCCT GGCCTTTGCC 660  
 CTGCCTTTTG TGGTCATCAC AGCCGCATAC GTGAGGATCC TGCAGCGCAT GACGTCCTCA 720  
 GTGGCCCCCG CCTCCCAGCG CAGCATCCGG CTGCGGACAA AGAGGGTGAC CCGCACAGCC 780  
 ATCGCCATCT GTCTGGTCTT CTTTGTGTGC TGGGCACCCT ACTATGTGCT ACAGCTGACC 840  
 CAGTTGTCCA TCAGCCGCCC GACCCTCACC TTTGTCTACT TATACAATGC GGCCATCAGC 900  
 TTGGGCTATG CCAACAGCTG CCTCAACCCC TTTGTGTACA TCGTGCTCTG TGAGACGTTC 960  
 CGCAAACGCT TGGTCCTGTC GGTGAAGCCT GCAGCCCAGG GGCAGCTTCG CGCTGTCAGC 1020  
 AACGCTCAGA CGGCTGACGA GGAGAGGACA GAAAGCAAAG GCACCTGAAC TAGT 1074

&lt;210&gt; 17

&lt;211&gt; 1283

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 17

AGTCGACATG TCAGTGGGAG CCATGAAGAA GGGAGTGGGG AGGGCAGTTG GGCTTGGAGG 60  
 CGGCAGCGGC TGCCAGGCTA CGGAGGAAGA CCCCCTTCCC AACTGCGGGG CTTGCGCTCC 120  
 GGGACAAGGT GGCAGGCGCT GGAGGCTGCC GCAGCCTGCG TGGGTGGAGG GGAGCTCAGC 180  
 TCGGTTGTGG GAGCAGGCGA CCGGCACTGG CTGGATGGAC CTGGAAGCCT CGCTGCTGCC 240  
 CACTGGTCCC AACGCCAGCA ACACCTCTGA TGGCCCCGAT AACCTCACTT CGGCAGGATC 300



13/15

GCCCAGCACA CAAAGAAGAC CAGACAGAUG GCGAUGGCUG UGCGGGUCAC CCUCUUUGUC 360

CGCAGCCGGA UGCUGCGCUG GGAGGCGGGG GCCACUGAGG ACGUCAUGCG CUGCAGGAUC 420

<210> 19

<211> 18

<212> PRT

<213> Rat

<223> The 6th cystein residue binds with the 15th cystein residue to form a intra-molecular disulfide-bond.

<400> 19

Phe Asp Met Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys Trp

1

5

10

15

Gln Val

18

<210> 20

<211> 17

<212> PRT

<213> Rat

<223> The 5th cystein residue binds with the 14th cystein residue to form a intra-molecular disulfide-bond.

<400> 20

Asp Met Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys Trp Gln

1

5

10

15

Val

17

<210> 21

<211> 16

<212> PRT

14/15

<213> Rat

<223> The 4th cystein residue binds with the 13th cystein residue to form a intra-molecular disulfide-bond.

<400> 21

Met Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys Trp Gln Val

1 5 10 15 16

<210> 22

<211> 15

<212> PRT

<213> Rat

<223> The 3rd cystein residue binds with the 12th cystein residue to form a intra-molecular disulfide-bond.

<400> 22

Leu Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys Trp Gln Val

1 5 10 15

<210> 23

<211> 14

<212> PRT

<213> Rat

<223> The 2nd cystein residue binds with the 11th cystein residue to form a intra-molecular disulfide-bond.

<400> 23

Arg Cys Met Leu Gly Arg Val Tyr Arg Pro Cys Trp Gln Val

1 5 10

<210> 24

<211> 13

<212> PRT



